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ABSTRACT
Class A serotonin (5-hydroxytryptamine) 2A (5-HT2AR) and class C metabotropic
glutamate 2 receptors (mGluR2) are seven transmembrane receptors (7TMRs or G
protein-coupled receptors – GPCRs) involved in multiple neuropsychiatric disorders
including schizophrenia. Previous findings from our laboratory reported that 5-HT2AR and
mGluR2 are dysregulated in the prefrontal cortex of patients suffering from this psychiatric
condition, although 5-HT2AR’s expression was recovered in antipsychotic-medicated
patients. Genome-wide association studies on schizophrenia reported that endosomal
trafficking that regulates cell surface abundance of another 7TMR implicated in this
disease (dopamine D2 receptor) can be altered. Ligand-activated receptors, including the
7TMR superfamily, are dynamic entities whose signaling depends on trafficking, and
trafficking on signaling. Impairments in the spatial and temporal regulation of 7TMRs result
in homeostasis perturbations and later in diseases. Like other cell surface proteins
expressed in mammals, such as enzyme-associated receptors and ligand-gated ion
channels, 7TMRs form homo- or hetero-oligomers, conferring novel and unique functional
properties to the complex. Our previous findings suggested that 5-HT2AR and mGluR2 are
assembled in a functional GPCR heteromeric complex in both heterologous expression
systems and in mouse and human brain frontal cortex. However, evidence that GPCR
heteromerization can directly affect receptor subcellular organization and localization is
missing, especially across classes. Here, we showed in mammalian HEK293 cells that 5HT2AR affected the localization and trafficking of mGluR2 through a mechanism that
required their physical assembly. In the absence of agonists, 5-HT2AR was primarily
localized within intracellular compartments. Intriguingly, the plasma membrane-localized
mGluR2 was redistributed in internal compartments when coexpressed with 5-HT2AR.
Agonists for either 5-HT2AR or mGluR2 differentially affected trafficking through Rab5- or
Rab7-positive endosomes in cells expressing the receptors alone, or together. In addition,
overnight blockade of 5-HT2AR with antipsychotic clozapine, but not with M100907,
decreased mGluR2 density through a mechanism that involved 5-HT2AR-mGluR2
heteromerization. Using TAT-tagged interfering peptides and a chimeric construct unable
to heteromerize with 5-HT2AR, we showed that heteromerization was necessary for the 5HT2AR-mediated co-trafficking of mGluR2. Furthermore, using bimolecular fluorescence
complementation (BiFC), we tracked the maturation of the 5-HT2AR-mGluR2 complex in
the endoplasmic reticulum and the Golgi apparatus. In accordance with our findings in
HEK293 cells, mGluR2/Rab5 colocalization was diminished in neuronal cortical primary
culture of 5-HT2AR-/- mice as compared to controls. Additionally, mGluR2 was mostly
localized near the plasmalemma in brain sections of 5-HT2AR-/- mice frontal cortex
glutamatergic excitatory postsynaptic compartments. Together, our data suggest that
GPCR heteromerization may itself represent a mechanism of receptor trafficking and
sorting.
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Introduction
7TMRs superfamily
With more than 800 members (a number that varies across studies) counting for about 2-3% of
the total human protein-encoding transcripts1–3, guanine nucleotide binding protein (G protein)coupled receptors (GPCRs), or more accurately, heptahelical or seven transmembrane receptors
(7TMRs), constitute the largest superfamily of spanning membrane proteins in the Metazoa and
the mammalian genome. Mammals express about 400 non-odorant 7TMRs4. As a matter of
comparison, the second largest family of receptors, the receptors-enzyme tyrosine kinase (RTK)
family counts about 58 receptor-types in 20 subfamilies5. Because they represent fundamental
interfaces between a tremendous diversity of extracellular stimuli*, triggering inner molecular
cascades, cellular responses and genes transcription, 7TMRs provide highly valuable targets for
clinical pharmacology. About 34% of FDA approved drugs target 107 unique 7TMRs, of which 27%
treat neuropsychiatric disorders6,7. Often termed metabotropic receptors, as opposed to ionotropic
receptors, whose activation and subsequent cell reaction is faster than the former, they process
and transduce signals throughout structural and biochemical steps much slower than receptor
channels. A cell response is always a combination and a cooperation between fast and slow
transmitters. The classical/canonical mode of signal transduction through 7TMRs cognate G
proteins is widely accepted, although recent findings proposed G protein independent signaling8–
10

. For a concern of accuracy over widely acceptance, this report will use the term 7TMRs.

7TMRs and G protein signaling likely appeared before Plants, Fungi and Animals, and diverged
from their common ancestor about 1.2 billion years ago11. Primitive structures of 7TMRs existed
in unicellular eukaryotes that resemble Metazoa cells12. The glutamate-receptor-like receptor is
one of the oldest. The serotonin receptors subfamily is also one of the oldest in class A/rhodopsin-

*

Stimuli can be exogenous chemical ligands such as drugs, vitamins, odorants, tastants, and viruses, and physical
stimuli such as photons. Endogenous ligands can be biogenic amines, nucleotides, hormones, large and small peptides,
cations and lipids, small molecule neurotransmitters, chemokines, and more.
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like 7TMRs, which appeared between 700 and 800 million years ago13. This evolutionary success
gives an idea of the robustness of such biostructures, having evolved and diversified under
selective pressure, to finally regulate almost all aspects of living organisms’ physiology. 7TMRs
share a minimal and unique common attribute that is the seven transmembrane α-helices domain
connected by three extracellular (EC1, EC2, EC3) and three intracellular (IC1, IC2, IC3) alternated
loops, in between an extracellular N-terminus and an intracellular C-terminus, often ended by a
so-called helix 8.
Classification of 7TMRs
All characterized 7TMRs, as well as the orphan 7TMRs, are classified and categorized within the
International Union of Basic and Clinical Pharmacology (IUPHAR) database†, which recognizes 6
classes, widely used among studies. Several other classifications are often based on structural
homology, but not only. 7TMRs are organized into 5 or 6 major nomenclatures according to their
sequence similarity and functional properties (A to F)14, as well as structural and ligand-binding
features (1 to 5)15. Also referenced phylogenetically as GRAFS16, acronym for Glutamate,
Rhodopsin, Adhesion, Frizzled/Taste2, Secretin, the rhodopsin-like or class A/1 is the most
represented subfamily in the human genome. The class A includes, with light-activated rhodopsin
and highly numerous olfactory receptors, monoaminergic norepinephrine, dopamine and
serotonin neurotransmitters/modulators transducers. Their homology of sequence indicates that
they also share palmitoylated cysteine at their C-terminal tail, as well as a triplet of
glutamic/aspartic acids - arginine/tyrosine termed E/DRY motif on their helix III17. This motif is the
target of a strong ionic interaction that is involved in receptor activation as shown for the 5-HT2A
receptor, thought to be a generalizable activation system within the class A18. Another shared
feature of class A receptors is that they harbor a long N-terminus with conserved cysteines17.
Class B/2 are secretin-like 7TMRs among which corticotrophin-releasing factor (CRFR1, CRFR2),

†

www.guidetopharmacology.org/GRAC/GPCRListForward?class=A
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parathyroid hormone (PTHR1, PTHR2) and glucagon-like peptide receptors (GLPR) among
others may be mentioned. Class C/3 regroups metabotropic glutamate (mGluR) and gammaaminobutyric

acid

type

B

receptors

(GABABR),

which

bind

respectively

the

main

excitatory/inhibitory neurotransmitters in the central nervous system (CNS), along with the sweet
and umami taste receptors (T1R1/2+3) and the calcium sensing receptors (CaSR). Classes D and
E constitute two minor families not represented in vertebrates, like cAMP receptor involved in
protozoan chemotaxis signaling, and class F includes frizzled/smoothened receptors19. Further
analogies between those nomenclatures remains unlikely since the criteria used are not conform.
Signal transduction
External ligands or stimuli are typically treated in two ways. Ionotropic receptors convey fast
information flux, whereas metabotropic receptors transmit signals slowly, engaging a series of
chemical and/or physical modifications from ligand binding to cell response. The signal
transduction can be simply represented as an information crossing a regulated field. Information,
the ligand, is treated, sorted and processed by the transmitter and its cognate G proteins, together
with intracellular signaling molecules. A series of phosphorylations takes place within cascades,
where the signal can be amplified and/or transmitted to the different target components. Because
cell’s phospholipid bilayer membrane must maintain the system closed and tightly regulated,
communications operate uniquely through transmitters and channels, or both, and by
endo/exocitic

vesicular

trafficking.

Nonetheless,

it

is

likely that

other

modes

exist

(gasotransmitters20).
Receptor activation starts with ligand binding that initiates conformational changes within the
seven transmembrane domains that resonate to receptor extremities, and convey signal
transduction through heterotrimeric αβγ G proteins’ subunits. The inactive state, reflecting basal
activity, remains stable during low ligand concentration. Upon binding of its ligand, receptor
changes its conformation that activates its cognate G protein. The activation/deactivation process
3

should not be envisioned as an on/off switch, with two distinct conformations. Receptors are in
constant and continuous vibration, oscillating between a multitude of different conformations,
toward active or inactive state, and get stabilized by the ligand21. It is considered as a multi-active
state model22.
The specificity of the GPCR-mediated signal transduction was initially thought to solely lay in the
dissociation of the trimeric G protein’s αβγ subunits upon ligand binding. The α subunit catalyzes
GDP to GTP to exchange and split from the tripartite GTPase to signal downstream effectors and
second messengers, while βγ is involved in regulating ions channels switching, as well as other
effector proteins. The GTPase family of G proteins is also well diversified, the four main G proteins
being Gαs, Gαi/o, Gαq/11 and Gα12/13. The first two respectively stimulate or reduce adenylyl cyclase
activity, resulting in the augmentation or the reduction of cyclic adenosine monophosphate (cAMP)
internal concentration. The cAMP-dependent protein kinase A (PKA) signal is amplified or
dampened accordingly, which modulates specific cell responses. A typical example is the human
class A Gαs-coupled β2 adrenergic receptor (β2AR), which triggers cardiac myocytes contraction
after binding of adrenaline in tissues involved in sympathetic neurotransmission26. Class C
mGluR2/3 glutamatergic receptors are linked to the Gαi/o pathway that inhibits cAMP production
and reduces glutamatergic tone in presynaptic terminals where it acts as an autoreceptor. The
class A 5-HT2A receptor provides an example of Gαq/11 coupling. Agonist binding stabilizes the
receptor in its active conformation that triggers the phospholipase C (PLC) DAG/IP3/PKC
pathway. For example, in 5-HT2AR-expressing neurons, the Gαq activates PLC-β which catalyzes
the hydrolysis of phosphatidyl inositol-bisphosphate (PI(4,5)P2) into two second messengers,
diacylglycerol (DAG) and inositol triphosphate (IP3). DAG remains attached to the membrane and
recruits the protein kinase C (PKC), while IP3 diffuses in the cytoplasm to trigger calcium release
from the endoplasmic reticulum storage. While diffused into the cytoplasm, Ca2+ can operate
several cellular events such as activation of PKC (feedback), stimulation of ionic channels and
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enzymes recruitment that together modulate synaptic transmission. The PKC is also involved in
triggering cellular responses, such as neuronal plasticity, cell survival, and transcription factors
activation. Several studies recently showed that the canonical linear model was not sufficient to
describe unexpected results while tracking G protein activation. This led to separate G proteindependent and -independent signaling8–10,23–26.
To prevent response overload, and/or to return to basal state, i.e. low ligand concentration, a
termination mechanism shuts down the signaling components by acting directly on the receptor,
typically involving two major pathways: the receptor phosphorylation by G protein-coupled
receptor kinases (GRK), and the subsequent recruitment of β-arrestins (1 or 2). GRK are recruited
by Gβγ once released upon ligand-dependent receptor activation and split from the α subunit, so
that receptor phosphorylation happens relatively fast after ligand binding. β-arrestins are thought
to specifically bind GRK-phosphorylated receptors while competing with the G proteins in the
vicinity. Arrestins are responsible for the recruitment of the endocytic machinery that involves
dynamin and the formation of clathrin-coated vesicles. Successive intracellular mechanisms such
as Rab-dependent desensitization (receptor endocytosis) and recycling from endosomes further
affect receptor’s fate and cell’s responsiveness.
7TMRs structure and oligomerization
Class A 7TMRs or rhodopsin-like receptors share the minimal features that defines the
superfamily, a seven transmembrane (TM) spanning helices domain, or heptahelical domain,
connected by three intracellular loops (IL1-3) and three extracellular loops (EL1-3). This class of
receptors has an extracellular cavity within their TM domain dedicated to the binding of the
orthosteric ligand. They have also in common few conserved motifs27. They are devoid of the large
extracellular bilobal domain (ECD) characteristic of the class C 7TMRs, the Venus Fly Trap (VTF)
domain. The typical receptors of this family, the GABAB and the metabotropic glutamate receptors
(mGluRs), share this VFT domain dedicated to the binding of the orthosteric ligand, as well as
5

holding a cysteine disulfide bridge necessary for the receptors obligatory dimerization. A cysteine
rich domain is also partially involved in the dimeric interface, and proposed to relay ligand-induced
conformal adjustment28. The lack of covalent bond between protomers have led some reports to
justify that class A dimers are not stable enough to remain bound supported by weak interactions29.
Class A receptor dimers are indeed less stable than class C30,31. This does not rule out that they
are functional. The rapid conversion between monomers and dimers and their resulting ratio may
regulate receptor function30.
Since the first biochemical findings showing that a peptide derived from a 2 adrenergic receptor
(β2-AR) transmembrane (TM) domain prevented both receptor complex formation and agonistpromoted stimulation of adenylyl cyclase activity32, the class A 7TMRs never ceased to attract
attention for their ability to associate as dimers or higher oligomers33,34. Despite certain limitations
and caveats of most biophysical and biochemical approaches and technologies, including
coimmunoprecipitation (CoIP), crosslinking, bioluminescence and Förster resonance energy
transfer (BRET/FRET), SNAP- or CLIP-tag35,36, bimolecular fluorescence complementation (BiFC)
and other protein complementation assays (PCA), these studies generally provide evidence
related to the fundamental role of class A 7TMR homo/heteromerization in the control and
regulation of both agonist-induced receptor-G protein coupling37,38 and trafficking39–43. Similarly,
contemporary advanced techniques such as single molecule imaging in intact cells indicate that
certain class A 7TMRs form stable homomers41,44–46, while others, using similar approaches, have
shown either transient interactions30,47,48, or negligible to absence of class A dimerization49–51.
Accordingly, many questions still remain open about the role of receptor complex formation in
7TMR’s dynamics and behavior.
Between 2000 and 2004, a series of articles published in the Journal of Biological Chemistry (JBC)
by several laboratories either directly implied the oligomeric association as a mean for 7TMRs to
undergo internalization after ligand binding or assumed that receptor oligomerization could
6

influence both trafficking and signaling. These results directly followed pioneer discoveries about
both class A and class C 7TMRs with the case of β2-AR and GABABR, respectively (see below).
Among those studies, the scope has been extended to several other subtypes, β2-AR
heterodimerization with β1-AR52–54, β2-AR with β3-AR55, oligomerization of other adrenergic
subtypes alpha, such as α1a- and α1b-AR56, but also across subtypes57. Likewise, an early study
demonstrated that the δ-opioid receptor dimerize, suggesting that such receptor-receptorinteraction (RRI) was particularly important for their desensitization and subsequent
internalization58,59. Dimerization was also found to play a critical role in the agonist-independent
desensitization and internalization of the human platelet-activating factor receptor (hPAFR)60.
These novel ideas also emerged within the opioid receptor subfamily following a series of impactful
discoveries, such as the oligomerization of the μ- and the δ-opioid receptors61, where again, the
scope extended the idea that those associations, this time among different protomer subtypes,
would create novel functional properties that was not previously observed by classical
pharmacological characterization. In the same journal, another study implicated heteromerization
of somatostatin and μ-opioid receptors as a principal component of the cross-phosphorylation and
the desensitization of both receptors62.
Although few studies directly implicated the 7TMRs homo/heteromerization in both endocytosis
and biosynthesis processes, several of them though clearly suggested that such interactions can
modulate function and trafficking. Opioid receptors were the first class A 7TMR to be thoroughly
studied following the discoveries of dimerization and oligomerization within the subfamily. The μand the δ-opioid receptors have been demonstrated to heterodimerize using epitope tagged
constructs submitted to subsequent immunoprecipitation. Moreover, whereas DAMGO (μ
selective agonist) did now affect desensitization of the receptors expressed together, treatment
with DPDPE (δ selective agonist) induced a resistance to desensitization and internalization of the
two receptors. Opioid receptors are well studied for their capacity to be internalized and
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desensitized after ligand binding. The fact that this process was affected by the coexpression and
the putative interaction between μ and δ suggested that heteromerization can also affect basic
components of class A receptors function such as internalization and desensitization61, as well as
binding affinities of the ligands63. These two studies published the same year demonstrated that
oligomerization is an important feature of the opioid receptor subfamily. Heterodimerization also
was demonstrated to create novel functions for the δ- and the κ-opioid receptors64. Although the
three opioid transmitters share a relatively high homology of sequence (about 65% identical amino
acids), the diversity of RRIs demonstrates a great variety of novel functions that affect most
aspects of receptor signaling and trafficking. Together these pioneer studies provided the first
indirect evidence that one protomer is able to affect both signaling and trafficking of another
protomer within the class they belong to.
Within the class C, aside from similar conclusions about the novel properties provided by receptor
homo/heteromerization, it has been shown that such associations are necessary for the proper
cell surface addressing of the protomers together, as a single entity. The classical case illustrated
by the class C GABABR remains remarkable as it is considered a paradigm. This obligate dimer
is composed by the GABABR1 protomer that is unable to trigger G protein-activated inwardly
rectifying K+ channels (GIRKs) signals alone, when overexpressed in mammalian cells: it requires
heterodimerization with GABABR2, a subsequently described protomer that shares 35% homology
with the subtype R165. The reason behind this resides in the early association of the two subunits;
while crossing the endoplasmic reticulum during the protomers biosynthesis, R2 masks a retention
motif lodged at the R1 C-terminus66,67, allowing the full heteromer to exit the ER, otherwise retained
in the organelle as single units. Here, heterodimerization is necessary for the cell surface
addressing of a functional GABABR. These findings also indicated that the GABAB receptor is an
obligate dimer. More recently, a group demonstrated that GABABR2 competes with a gatekeeper
protein termed PRAF2, which results in passing prerequisite quality controls prior to ER exit68. It
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highlights that 7TMRs can hold the role of chaperonin-like proteins, although finely regulated by
resident chaperone molecules69–71. Similarly, the class A β2-AR homodimerizes in the ER to allow
upward trafficking to the plasma membrane. Using two different mutation approaches, it was
revealed that retention/export motifs mutants act as dominant negative on WT β 2-AR species,
precluding their ER export and migration to the cell surface: first, by generating a chimera where
the C-terminus tail of the β2-AR is interchanged with that of GABABR1, containing the abovementioned retention motif; second, by mutating an ER export signal from the D1R sequence in
order to generate an unrecognizable binding site for specific resident proteins involved in the ER
exit of D1R. The structure/function role of such coupling has also been illustrated by the required
dimerization of metabotropic glutamate receptor 2 to enable ligand-induced G protein activation,
while monomeric 7TM domain appears sufficient for its coupling72, supporting the idea that dimers
are the minimal signaling units, constituting a 2:1 ratio with the G protein they are associated to70.
Although truncated mGluR2 lacking their ECD can homodimerize using only the 7TM interface,
the stability of this formation is assured by the cysteine 121 located in the VFT that provides a
covalent intersubunit disulfide bound. Isolation of truncated receptors (purified 7TM domains) in
lipid nanodiscs producing two different fractions enriched with two or one receptor, mGluR2 was
able to signal with the latter fraction using positive allosteric modulator (PAM), which binds the
ECD, but not the VFT. However, truncated mGluR2 lacking the VFT domain were unable to
activate the G protein in presence of the orthosteric ligand glutamate, supporting the fact that only
full length dimeric species can activate Gαi protein signaling as assessed by GTPγS assay, while
monomeric species are sufficient to the coupling to the G protein73.
The accurate description of the interactions between residues that hold weak forces and stabilize
oligomeric interfaces is an essential component of the pharmacological properties of 7TMRs,
besides providing important information for the development of therapeutics and 3D models, which
simulate dynamic structures and interactions at the atomic level. Advances in structural biology
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technologies have allowed to elucidate and validate the precise transmembrane domains and
often the residues involved in the conformations responsible for the activation/deactivation of
oligomeric receptors. Across studies, TM domains I, IV and V typically appear to be the implicated
interfaces in the formation of transient and/or stable class A 7TMRs oligomers74.
How TM domains associate is well illustrated by the class C metabotropic glutamate receptors,
which exhibit the most stable RRI within the superfamily. It was first proposed that the mGlu5
receptor is a naturally occurring dimer linked by a disulfide bound at the extracellular domain, and
that concept could be generalizable to all mGluRs75. The prototypic class A dimerization held by
the μ-opioid receptor has been challenged, suggesting that the dimer populations are scarce and
negligible at physiological concentrations51. Nevertheless, a great majority of theoretical
approaches remain in favor of receptor oligomerization that provides an array of supplementary
functions: antagonistic assemblies to cross-modulate protomer signaling, chaperones and guides
through the biosynthesis pathway, subcellular co-trafficking and co-desensitization: dynamic or
stable, kiss-and-fly or covalent76,77.
In a review focused on class A 7TMRs homo/heterodimerization, several studies are listed
according to the technique used and the involvement of the TM interaction to stabilize the dimeric
formation, seven of nine class A receptor homo/heterodimers involve at least the TM IV and/or TM
V. In a second chart similar findings are proposed78. The diversity of the TM interaction is provided
by the highly flexible linkers and loops that allow fast conformational modifications and relatively
large movements of the TM domain78,79. TM I and II were also mentioned for the muscarinic
receptor 3 (M3), suggesting that each combination of the transmembrane interfaces is specific to
a mode of functioning, either active or inactive states74. At the time of this report, a study elucidated
the active and inactive conformation used by the mGluR2 dimer to activate Gαi protein using
cryoEM technology, showing asymmetric positioning of the TM helices both during activation and
at basal inactive state, involving TM III/IV, and TM VI/VI respectively80.
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As illustrated by the muscarinic acetylcholine receptor 2 (M2R) case, which has been found as
monomeric, but also in dimeric and tetrameric forms by three different studies using different
techniques and systems, class A 7TMRs could associate in various homomeric ratios74,81–83.
Although discrepancies for the same target receptor may be interpreted as a lack of reproducibility,
feeding the debate on class A 7TMRs oligomerization, it might instead indicate that each study
has revealed a different state of this receptor at a different time and under different conditions, as
has been noted,
“Until recently, these were often considered to be mutually exclusive scenarios, but the coexistence and potential interchange between such forms, based in part simply upon mass action,
has resulted in a more textured view.”84
Receptor oligomers can be formed by different mechanisms, by weak forces at the plasma
membrane, or covalently during biosynthesis. The origin of the coupling must have a physiological
significance85–87. Homo or heterodimerization most likely occurs within the same 7TMRs classes
due to more compatible structural homology of their TM domain15,70, the natural interface of
receptor coupling. Nevertheless, interclass receptor associations are progressively more
reported86. A remarkable association has yet been suggested for the 5-HT2R and the CRFR188. In
this proposed model, 5-HT2R cell surface expression and signaling is increased by agoniststimulated CRFR1 trafficking. The accuracy in detecting the physical interaction at the interface of
TM dimerization starts to provide more granular visualization on how oligomers associate and
function89. The proof provided by visual evidence is also a criteria in favor of 7TMRs
oligomerization90. Finally, the theory of moonlighting proteins, as a powerful and economic natural
feature of proteins to organize, associate and function, support the idea that (receptor)
oligomerization is not a rare and fortuitous event, but rather a common mechanism found
everywhere that enables complexity and diversity91–93.
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Serotonin
Serotonin is the first neurotransmitter/trophic factor to appear in both Protozoan and Metazoan 94,
probably inherited from unicellular eukaryotic precursors, which likely firstly evolved in
mitochondria a billion years ago95. Plants produce a large amount of serotonin for both trophic
factor that regulates growth together with auxin and antioxidants to preserve cell from damages
provoked by excessive production of molecular oxygen96. Serotonin-based analogs and alkaloids
such as ibogaine, mescaline, dimethyltryptamine (DMT) and psilocybin (in the Fungi) are produced
by plants and fungi to resolve the problem of oxidation and protect them from radical oxygen,
which is intrinsic to their photosynthetic abilities95. Serotonin is a biogenic amine synthetized from
indole precursor tryptophan primarily after its hydroxylation into 5-hydroxytryptophan by the
tryptophan hydroxylase enzyme. Its product subsequently undergoes a decarboxylation by a
decarboxylase enzyme in presence of the cofactor pyridoxal phosphate which produces 5hydroxytryptamin (5-HT). Serotonin does not cross the blood brain barrier (BBB) but L-tryptophan
does, being the rate-limiting precursor for the synthesis of serotonin. After being released
presynaptically in the extracellular milieu (synaptic cleft), serotonin is either metabolized by
monoamine oxidase (MAO) into 5-hydroxy indole acetic acid (5-HIAA), or recycled by serotonin
reuptake transporter (SERT) or autoreceptors. 5-HIAA is an interesting metabolite that could be
used as a marker because of its suggested abnormal levels in psychiatric disorders (often found
as decreased), reflecting serotonin levels in the brain97. Altered blood, serum or cerebrospinal fluid
(CSF) levels of both serotonin and its metabolites have been associated with impulsive and
aggressive behaviors in general98–102 and in suicide103–106 and autism107–111 in particular, although
these findings are still under debate112.
Serotonin can be found in all human body tissues and fluids. In the CNS, it modulates a large
number of cerebral, cognitive, hormonal and emotional functions. Mood, appetite and sleep,
aggressive and sexual behaviors, locomotion, learning and memory consolidation are all regulated
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by serotoninergic neurons. Additionally, it regulates pulmonary and cardiovascular physiology,
hemostasis, and endocrine functions. As a trophic factor, it is involved in neural development,
homeostasis and plasticity. Serotonin is synthesized in dorsal raphe nuclei located in the primitive
brainstem, but about 95% is found in blood platelets, insuring aggregation and vasoconstriction of
blood vessels, and in enterochromaffin cells within the digestive apparatus113. The remaining
synthesized neurotransmitters are delivered throughout the entire brain using outputs originating
from the caudal raphe to innervate the spinal cord, while medial and dorsal raphe nuclei project
toward almost all brain areas113,114 (for a map of the main serotonin projections in the brain and
the spinal cord, see figure 7 in ref96). Within the forebrain, the frontal cortex, together with the
corpus striatum, the lateral region of the hypothalamus and the amygdala are innervated by
projections issuing from the dorsal division of the nucleus centralis superior96. An exhaustive listing
of the areas innervated by the dorsal raphe is not relevant for this report, but the extent to which
serotonin influences the overall brain activity by its ubiquitous presence demonstrates its
pleiotropic role over all other monoamines115. All effects and regulatory processes controlled or
modulated by serotonin necessitate its interaction with serotonin receptors.
Serotonin receptors
The serotonin receptors appear to be among the oldest neurotransmitter receptor system within
the rhodopsin-like 7TMR subfamily11,116. All subtypes are expressed in the CNS by nineteen genes
(14 metabotropic receptors and 5 ionotropic receptor subunits) coding for seven different receptor
types composed by nineteen different subtypes. Except for the 5-HT3 receptor (constituted by 5
subunits 5-HT3(A,B,C,D,E)) forming a pentameric structure) which are a cys-loop ligand-gated ion
channels activating inward K+/Na+ currents117,118, all other receptors are metabotropic and
classified in three categories according to their G protein signaling. The 5-HT1A, 5-HT1B, 5-HT1D, 5HT1E, 5-HT1F and the 5-HT5A, 5-HT5B receptors are inhibiting cAMP accumulation after release of
the Gαi/o subunit following receptor activation. The 5-HT1CR has been revealed to be the 5-HT2CR
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receptor. Conversely, the 5-HT4, 5-HT6 and 5-HT7 are Gαs-coupled and stimulate cAMP production
in cells. The subtype 2 regroups the 5-HT2A, 5-HT2B and 5-HT2C mostly coupled to production of
IP3 and DAG after hydrolysis of PIP2 following activation of the Gαq/11 pathway, also stimulating
PLC and PKC.
5-HT2A receptor
The class A 5-HT2A receptor, encoded by the HTR2A gene, is a subtype of the 5hydroxytryptamine receptors type 2 and shares this subgroup with 5-HT2B and 5-HT2C receptors.
These subgroup 2 receptors share 45-60% of sequence homology and are coupled to their
canonical Gαq/11 signaling pathway119. Although found outside the CNS, a study provided evidence
that serotonin-induced activation of 5-HT2AR in cultured rat renal cells produced about 50%
inhibition of forskolin-stimulated cAMP accumulation, a signal that was reversed by application of
the antagonist ketanserin, indicating that this mainly Gαq/11 coupled receptor can activate Gαi/o
signaling pathway, at least in this peculiar primary culture120.
The 5-HT2AR is by far one of the most studied 7TMR and consequently, one of the most known
serotonin receptor121. This is in part due to its atypical and unique pharmacology, as well as its
wide distribution in the CNS and substantial involvement in neuropsychiatric disorders.
5-HT2A receptor distribution
A recent study analyzed the human biodistribution of the 5-HT2AR by positron emission
tomography (PET) with two specific radioligands and showed a wide expression in numerous
organs and tissues122. In the brain, it is well characterized and widely distributed in Rodents123 and
non-human Primates124, and although mostly present in postsynaptic neurons125–127, its
presynaptic activity has been demonstrated124,126–128. It is also present on astrocytes127,129. In rat
and human, [3H]ketanserin radioligand binding co-distributes and overlaps with mRNA
histochemistry demonstrating dense labelling of the major parts of the cerebral cortex regions,
though denser in laminae I, IV and Va, the piriform and the entorhinal cortexes, as well as the
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claustrum119. Using another 5-HT2AR radioligand antagonist, [3H]MDL100,907, radiolabeling
signals coupled to in situ hybridization (ISH) showed a matching overlap of both transcripts and
protein in the rat brain, confirming most of the cortical regions previously described in Mammals
and in Rodents, with a preference for the layer V of prefrontal cortex pyramidal neurons130. Lesser
densities are found in the basal ganglia, in particular the caudate-putamen nucleus (CPN) and the
nucleus accumbens (NAc). The cerebellum seems exempt of signal across many studies and
often used as a control or reference area119,131,132, however some findings involved serotonin
receptor localization and dysfunction in this area in humans and in rats133,134. Caution must be
taken about the specificity of the radioligands used to label expressed receptors prior to the
development of [3H]MDL100,907114,135 and [11C]-Cimbi-36136, accounting for their technical
limitations and caveats114.
In situ hybridization enabled to localize 5-HT2AR mRNA in diverse cell types of the rat brain, mostly
pyramidal neurons of the neocortex and the hippocampus, as well as interneurons of the piriform
cortex132. The lamina IVc of the human striate cortex also showed positive signal. Immunoreactivity
in the rat brain displays dense staining in the apical dendrites of pyramidal shaped neurons of the
neocortex, as well as both parvalbumin positive and negative interneuron bodies137.
The cellular and subcellular distribution of this receptor remains difficult to ascertain. Despite
numerous examples of its localization both at the plasma membrane and within neuron somas,
there is to date no definitive accordance on its spatial distribution either in heterologous cell
systems or in native tissues. It is however accepted that 5-HT2AR acts both intracellularly and as
a prototypical plasma membranous 7TMR depending on the brain regions and/or the
neuronal/peripheral function involved (see discussion below). Therefore, the localization of the 5HT2AR may affect both its trafficking and signaling properties, and vise-versa.
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5-HT2A receptor pharmacology
5-HT2A receptor is the target of endogenous neuromodulator serotonin (5-HT). It is also targeted
by atypical antipsychotics (AAP) such as clozapine, olanzapine, quetiapine, paliperidone,
aripripazole and risperidone, but also M100907, altanserin, mianserin, and ketanserin, acting as
inverse agonists or neutral antagonists. It is also bound by agonists and partial agonists among a
wide range of hallucinogenic compounds (HAL) which effects are psychedelic, phenethylaminelike, e.g. DOI, DOB, and indolamine-like, e.g. mescaline, dimethytryptamine (DMT), psilocybin,
lysergic acid diethylamide (LSD), acting as partial agonists138–140. Remarkably, some compounds
are not hallucinogenic (NHAL) (e.g. lisuride, ergotamine) despite high molecular similarity with
HALs. 5-HT2AR thus exhibits a singular pharmacology141, being the primary target of pro- and
antipsychotic drugs114,140,142,143. Such psychedelic compounds elicit response in humans that
profoundly affects behavior and consciousness139,144. In peak phases, this singular response is
often compared to delusions and hallucinations that resemble acute positive symptoms of the
schizophrenia spectrum disorder145,146. However, while psilocybin provokes psychosis-like
behavior in healthy volunteers via 5-HT2AR activation138, other agonists, including psilocybin, are
currently considered as potential treatment for depression and other psychiatric conditions147–155.
This is indeed of particular interest for psychiatric disorders and related pharmacology, because
HALs are employed to model psychosis in Rodents and in Humans138,156. Activation of 5-HT2AR is
not sufficient to elicit hallucinogenic response, but it is necessary140,143,157.
5-HT2A receptor signaling and trafficking
Serotonin regulates essential functions in the CNS such as mood appetite and sleep, along with
peripheral vasoconstriction and organs development. The 5-HT2AR transduction model describes
the Gαq/11-coupled signaling pathway upon ligand binding, stimulating PKC through PLC
recruitment, to finally mobilize calcium release from the ER158. The trafficking of the 5-HT2AR has
been described as atypical. Internalized by either agonists or antagonists, this is a specificity
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hardly found in other classes and other types of 7TMR159,160. The 5-HT2AR is also thought to
activate pathways differentially and promote agonist-directed trafficking of receptor stimulus161.
Latter termed “biased agonism”, this functional selectivity has been shown to differentially signal
downstream upon activation by either psychedelic or non-psychedelic agents. While canonical
signaling through Gαq/11 would be responsible for non-hallucinogenic-mediated downstream
activation, hallucinogens require in addition to signal through pertussis toxin-sensitive Gαi/o
pathways140,162. Similar to this concept of signaling, it has also been shown that the 5-HT2AR is at
the center of a biased phosphorylation which provides additional trafficking and internalization
selectivity through the β-arrestin dependent pathway163. While ERK-dependent phosphorylation
by HAL such as LSD and DOI is abolished by pretreatment with pertussis toxin, ergotamine and
lisuride NHAL signaling remained unaffected, comforting the idea that two G protein-activated
pathways are required to elicit hallucination-like behavior in vivo, using the Head-Twitch Response
as a proxy of hallucinogenic intoxication response in mice164) or the ERK signaling readout in
pyramidal neurons, as well as in in vitro heterologous systems114.
5-HT2A receptor oligomerization
The 5-HT2AR has been shown to form homo/heterodimers165–170 and oligomers with other
7TMRs171–175. Several lines of evidence have shown that 5-HT1A and 5-HT2A receptors, which are
co-expressed in cortical pyramidal neurons, form an antagonistic receptor heteromer by
modulating NMDAR currents114. 5-HT2AR and D2R have been shown to associate as a functional
receptor heteromer eliciting a signaling crosstalk signaling in cells172,176.
Physiopathology of the 5-HT2A receptor
5-HT2A receptor is involved in the pathophysiology of schizophrenia-like phenotypes, depression
and suicide, to name a few131,177–187. It has been linked along with other subtypes to
physiopathology of psychiatric and cognitive disorders, such as mood disorders and depression,
suicide and schizophrenia, associative learning, where preferentially affecting areas regrouped in
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the neocortex, in which the prefrontal cortex (PFC) seems to play an important
role124,125,143,183,187,188. The list of disorders implicating the 5-HT2AR is long, and it is clear that the
receptor regulate many diverse systems and functions in the body and the brain; it comprises
Alzheimer disease, autism, Parkinson disease, obsessive compulsive disorder, addiction, suicide,
cardiovascular lung and skin disorders, as well as diabetes and inflammation, to name a few. What
is unclear though, is how dysregulated is the receptor in many neuropsychiatric disorders.
Discrepancies about the level of 5-HT2A protein and mRNA, often is post-mortem human brains,
is still a matter of debate185,189.
Glutamate
Neurotransmission in the mammalian brain is usually depicted as a synchrony between excitatory
and inhibitory electrochemical signals. L-glutamate is known to be the main excitatory190,191 and
the most abundant192 non-essential amino acid in the mammalian CNS, while GABA relays
inhibitory neurotransmission. Glutamate concentration is high in the CNS, partly because it is not
solely used for excitatory neurotransmission, thus holding other metabolic activities in glia and
neurons193. Both glutamate and GABA are synthesized from glutamine precursor. Glutamine is
synthetized from glutamate by ATP-dependent glutamine synthetase in astrocytes. Glutamine is
exported to the neuron by glycine/glutamine transporters. In the neuron, it is then converted into
glutamate by the phosphate-activated glutaminase194. Glutamate is decarboxylated by the
glutamic acid decarboxylase in presence of cofactor pyridoxal phosphate and converted into
GABA. After vesicular glutamate transporter 1 (VGLUT-1)-mediated packaging of glutamate in
synaptic vesicles, it is released to bind both post synaptic ionotropic and post/presynaptic
metabotropic glutamate receptors/autoreceptors respectively. This results in modulation of Ca2+
release, acting as a second messenger required for the activation of signaling cascades. It is
removed from the synaptic cleft back to the astrocytes through transmembranous excitatory amino
acid transporter (EEAT), thus completing the glutamate-GABA/glutamine cycle. It also suggests
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the existence of different pools of glutamate-containing neural cells, providing the resources to
tightly regulate glutamine, glutamate and GABA homeostasis in the brain. Glutamate
concentration is maximal intracellularly, and extracellular increase of glutamate produce neuron’s
excitotoxicity195–197.
Glutamate receptors
As mentioned above, there are two types of glutamate receptors expressed in the CNS. Ionotropic
glutamate receptors (iGluRs) are fast-acting ligand-gated ion channels that are non-selective
cations channels, thus mainly exchanging Na+ and K+, together with lesser concentration of Ca2+
(in the case of NMDAR). They are termed according to their main activating ligand: NMDA (Nmethyl-D-aspartate), AMPA (α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate), and kainate
(kainic acid) receptors. As cation channel, their carry out excitatory post synaptic currents resulting
in cell depolarization and in optimal cases, creation of an action potential. As their related
metabotropic cousins, iGluRs can be both pre- and post-synaptic, complexifying the simplistic
black and white view on presynaptic mGluRs and postsynaptic iGluRs198. Slow modulation of
glutamate release is accomplished by metabotropic glutamate receptors (mGluRs). Indeed, the
role of mGluRs differs from that of fast-acting ion channels, because they can be sensitive to both
orthosteric and allosteric pharmacological compounds and drugs, thus changing the excitability of
the postsynaptic neurons. Additionally, their G protein coupling triggers intracellular messengers
that affect neuron homeostasis, function and transmission.
To date, the class C 7TMRs mGluRs are categorized into 3 different groups according to their G
protein coupling and sequence homology199,200. Splicing variants are common in this subfamily
(subscript letters). Group I contains Gαq/αs-mediated signaling subtypes, mGlu1(a, b, c, d, e, f), tastemGluR1 and mGlu5(a,

b)

receptors. Group II and III are mainly inhibitory-mediated signaling,

coupled to Gαi protein, decreasing adenylyl cyclase activity, stimulating K+ inward ion channels
and altering Ca2+ currents, thus negatively affecting neurons firing and excitability by an overall
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reduction of glutamate neurotransmission. Group III is composed by mGlu4 and taste-mGlu4 (a
shortened, less sensitive version of mGluR4201) receptors, the retinal mGlu6(a,

b, c)

and the

presynaptic mGlu7(a, b, c, d, e) and mGlu8(a, b, c) receptors. mGlu2 and mGlu3(A2, A4, A2A3) receptors form
the Group II, sharing homology of structure and Gαq protein signaling and pharmacological
characteristics. They all bear a large extracellular domain responsible for the binding of orthosteric
ligands, the VFT.
mGlu2, mGlu3 receptors distribution
Group II mGluRs are encoded by the GRM2 and the GRM3 genes. The homology of sequence
between the two genes approximates 67%, with 70% among the conserved regions between
mGluR1, 2, 3, and 4, especially at the c-terminus and at the VFT domain. Besides, they do not
share any similarly with the other 7TMR classes202. In situ hybridization studies indicate a wide
distribution of mGluR2 in discrete cell types in the rat CNS. It is high in the olfactory bulb and the
cerebral cortex. Immunohistochemistry studies with a specific mGluR2/3 antibody showed
expression of both receptors in many regions of the mouse brain with variable expression patterns
and intensities. This suggests that a wide array of subregions where both receptors are
coexpressed and possibly interact203. Additionally, the cell types are distinguishable among
regions but both pre- and post-synaptic neurons are positive for either mRNAs or protein
expression of mGluR2/3, as well as substantial glial expression203. In the cerebral cortex, layer I
to IV were highly stained, as well as deeper regions in the layer V and VI of medium and pyramidal
neurons203. Other important reactive regions were the piriform, frontal and entorhinal cortexes,
subregions of the hippocampus, the thalamus, and main nuclei of the basal ganglia such as
nucleus accumbens and caudate putamen. A study using autoradiography coupled to
electrophysiology with the selective mGluR2/3 radioagonist [3H]LY459477 in WT, mGluR2-/- and
mGluR3-/- mice, to specifically address distribution of each receptor, matched most of the regions
cited above in CD-1 mice204. In the basal ganglia, no signal could be found outside the substantia
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nigra, though both caudate-putamen and nucleus accumbens shell were mGluR2 positive, in
accordance with monoclonal antibody immunoreactivity in both mouse and rat, which also
detected mGluR2 in the ventral tegmental area (VTA)205. mGluR3 was also found in the same
subcortical regions with high immunolabeling ultrastructure resolution206. The claustrum was also
positive for mGluR2 and mGluR3 radioactivity with different amounts, although the above study
using immunohistochemistry technique reported a weak signal205. This study204 was also able to
differentiate regions expressing either mGluR2, such as prefrontal cortex, and mGluR3, such as
dorsolateral and entorhinal cortexes.
Whereas electron microscopy study found mGluR2/3 staining in many glial processes, vesicles of
putative excitatory synapses, presynaptic terminals near synaptic clefts of the layer I cerebral
cortex, signal was also high in postsynaptic small spine synapses. Glial staining was detected in
all layers, although the authors commented on the difficulty to delineate accurately the processes
that seemed positive203. Conversely, no glial cell expressing mGluR2 were found with monoclonal
immunostaining technique at the EM resolution205. Subsequently, other EM studies demonstrated
the presence of mGluR2/3 in astrocytic bodies that ensheathed glutamatergic-like synapses, and
confirmed the localization of both receptors indistinctly in pre- and post-synaptic processes such
as axons, dendrites and spines of the dorsolateral prefrontal cortex of non-human Primates207. In
the same region of the same animal model, it was specified the relative amount and presence of
both mGluR2 and mGluR3. Because this region is critical for many neurodegenerative and
psychiatric disorders, the localization of group II mGluRs invests a substantial importance.
mGluR2 is mostly reported as a presynaptic terminals autoreceptor200,208–210, and, to a lesser
extent, on a variety of spines, but mostly as an extrasynaptic receptor. It was also clearly present
in astrocytes although previously thought to be absent in glia205; mGluR3 seemed to be the
prominent glial receptor211. mGluR3 was mostly present on astrocytes and postsynaptic spines,
where it was shown to negatively modulate cAMP production212. These findings suggested, in the

21

context of delayed neurons firing in the layer II of the dorsolateral prefrontal cortex, that mGluR2
and mGluR3 have distinct functional roles in distinct regions of the tripartite synapse, although it
was previously assumed that they could share similar brain functions, where mGluR2 was
assumed to reduce neurons sensitivity together with other Gαi-coupled mGluRs200,213,214, while
mGluR3 would act as a potent mechanism of reuptake glutamate following vesicular release in
the extracellular field of excitatory glutamatergic terminals197.
Most of these regions also express the 5-HT2AR, in particular the layer Va of the prefrontal cortex
that showed dual labelling of [3H]LY459477 and either [125I]DOI or [3H]M100907 (in mGluR3 KO
mice)204, indicating that 5-HT2AR and mGluR2 co-distributed in critical regions involved in
neuropsychiatric disorders, as previously reported130. Both receptors are expressed and detected
in thalamic regions, the prefrontal cortex, hippocampal subregions such as the entorhinal cortex,
as well as the dorsal and ventral striatum and the amygdala204.
mGlu2, mGlu3 receptors pharmacology
Group II mGluRs can be sensitive to the same agonists as of their ionotropic cousins. Glutamate
is obviously one of them, but also quisqualate, which initially served as a selective agonist for
mGluR2 and mGluR3 with differential cellular electrophysiology in cloned expressed
receptors200,202. As of today, and to our knowledge, agonists sufficiently selective to distinguish
mGluR2 from mGluR3 are still not available. This is due to the sequence proximity at the
extracellular orthosteric binding site. Pharmacological design has however progressed in the
selectivity of this Group II agonists, and a compound, partial agonist at mGluR2 and antagonist at
mGluR3 has been developed and tested215. Another compound, N-acetylaspartylglutamate
(NAAG), the most abundant peptide in the mammalian brain, elicited high mGluR3 selectivity but
not at other mGluRs, including mGluR2, implicated in synaptic plasticity and neuroprotection
against excitotoxicity216,217. Although selective, it remains an endogenous mGlu3 receptor agonist.
Other agents could possibly be used in some cases, but the constraints over group II mGluRs
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pharmacology limit studies that would be able to distinguish the exact role held by each receptor.
This issue can be somewhat overcome by the recent availability of positive and negative allosteric
modulators, (PAM or ago-PAM and NAM respectively218–220).
The development of highly selective orthosteric mGluR2/3 agonists such as LY379268,
LY354740, LY2140023 (the LY404039 prodrug) and LY404039 enabled to refine the function of
each receptor in experiments in vitro, but also in clinical trials to treat neuropsychiatric disorders
such as schizophrenia and anxiety, stress and neurodegeneration, and even cancer and pain
management, to name a few221–235. Additionally, the affinity of such drugs can differ from one brain
area to another, or across different neuronal cell types236. LY379268, LY2140023 (the LY404039
prodrug) and LY404039 suppress the behavioral and physiological effects of psychotomimetic
drugs and serotonergic hallucinogenic drugs, both enhancers of glutamate release, and show their
efficacy in the treatment of schizophrenia211. The metabotropic glutamate receptors, including
mGluR2 and mGluR3 are considered new targets for their antipsychotic activity and, despite
undergone a hold in clinical application, their effects on the positive, negative and cognitive
symptoms of schizophrenia continue to raise hopes170,218,226,234,237–240.
mGlu2, mGlu3 receptors signaling
Because of their similarity in residues sequence, cognate G protein and pharmacology, it has long
been assumed that they also share function and similar roles in the brain, despite being localized
in different amounts in different localizations and cellular types. The overall decrease of
glutamatergic excitability follows the reduction of presynaptic vesicle release caused by the
inhibition of Ca2+ inward currents. Moreover, ligand-induced dissociation of the Gαi protein βγ
subunit can signal through a wide array of second messengers, typically the mitogen-activated
protein kinase (MAPK) and the extracellular signal-regulated protein kinases (ERK) pathways,
mediated by the phosphatidylinositol 3 kinase (PI3K)241. This is a fundamental signaling route
involved in critical cellular responses such as cell proliferation and transcription factors regulation.
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The loss of function remains a pertinent strategy to decipher to study the role of a protein or a
gene. As mGluR2 and mGluR3 being very close on many aspects, the use of knock-out animal
models, or even double knock-outs, has provided important information about the precise
functions of each receptor in the rodent brain. It offers a unique way to study such features, coping
with the issue of non-selective agonists within the mGluRs group II. To that end, several studies
have attempted to discern the specific role of mGluR2 over mGluR3 in pain242, cognition, arousal
and anxiety239,243, and the circadian system244. With regards to circadian rhythm and sleep
disruption, it is a comorbid symptom of schizophrenia, affecting 30-80% of patients245. When mice
were depleted of both mGluR2 and mGluR3, their sleep was perturbed, reduced and fragmented,
implicating group II mGluRs in sleep regulation244. It also suggests a possible link between the
implication of both receptors in schizophrenia and such perturbations of fundamental
physiology246. The above-mentioned mGluR2 agonists are used in clinical trial to test a new kind
of antipsychotics or anxiolytic medications, among other targeted neuropsychiatric disorders. They
were suggested to show reduced heavy side effects associated with atypical antipsychotics or
benzodiazepines. Although there is to date no correlation between the GRM2 gene and
schizophrenia, GRM3 abnormalities however have been detected multiple times in genome of
patients suffering from this syndrome.
mGlu2 receptor oligomerization
As mentioned above, class C 7TMRs are obligate dimers though their function in signaling G
protein is mitigate by their stoichiometry. They also form heterodimer within their class and across
subtypes, including mGluR2/mGluR3 heterodimers240,247–249.
Pathophysiology of the mGlu2 receptor
Some authors have associated schizophrenic phenotype with mutations within mGlu receptor
genes GRM2 and GRM3211. Altered dimerization of type 3 has been implicated in schizophrenia250.
Structural

and

functional

interactions

have

been

reported

for

the

mGluR2-5-HT2A
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heterocomplex183,251–254. Both receptors, but especially mGluR2 has been the center of intense
researches for its potential antipsychotic activity with potentially less side effects.
Summary
Given the number of matched regions expressing either 5-HT2AR, mGluR2 and mGluR3, there is
a high probability that a single neuron expresses these receptors or receives input from one and
expresses the second. Because their synaptic localization is also pre- and postsynaptic, as well
as glial, (i.e. all membranes and soma of the tripartite synapse), it increases the probability for a
functional role of the interaction formed by 5-HT2AR and mGluR2 or by mGluR2 and mGluR3 (or
by 5-HT2AR and mGluR3 even if they do not seem to interact directly183). Together this information
provides evidence and leads in the involvement of 5-HT2A and mGlu2 receptors, in participating in
brain functions and their alterations. They co-distribute and colocalize, their antagonistic signaling
is physiologically relevant and different from each other canonical signaling 255–257. Moreover, the
absence of one affects the behavioral effect of the other. All those criteria are consistent to the
required properties necessitated by a receptor heteromer86.
5-HT2A-mGlu2 receptor heterocomplex
Those two receptors have been reported to play independently and then likely as a heterocomplex,
significant roles in psychiatric disorders and especially schizophrenia183. As previously mentioned,
the PFC represents the area of interest demonstrated by previous electrophysiological studies
that suggested an antagonistic crosstalk125. In situ hybridization experiments reported that both
receptors are co-transcribed in pyramidal neurons of mouse cortex and human PFC, where they
co-immunoprecipitate and show close molecular and functional interactions revealed by B/FRET
analyses coupled to functional assays, excluding 5-HT2A/mGluR3 assembling183,252. Electron
microscopy by immunogold particles colocalization confirmed close proximity in ultrastructural
resolution of pre- and post-synaptic elements252. Additionally, this interclass association
modulates Gαq and Gαi pathways in an antagonistic and specific manner and support evidences
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of heteromeric structures with physiological relevance67,69,70,251,254. The structure interface
responsible for their heteromerization has been established by a mutation study of the TM4 of the
glutamate receptor252. In follow up experiments, these findings have been corroborated using
photocrosslinking assay, where the covalent linkage between the unnatural amino acids in the TM
regions occurs within a distance of 2-4 Å89.
7TMR trafficking and biosynthesis
7TMRs are synthesized throughout the maturation pathway from ribosomal translation processes
at the edge of the endoplasmic reticulum where they are folded and glycosylated, undergoing
quality control checkpoints258. The Golgi apparatus constitutes the exit pathway as an active posttranslational element, finalizing 7TMR biosynthesis. This export process is highly regulated by
cargo and scaffold proteins70,258. 7TMRs are described as actual signaling units when reaching
the plasma membrane, but increasing evidence suggest signaling can occur from endosomes259.
It is also of particular interest that 7TMR signaling may occur during their trafficking stages260.
Although it is not the case for all of them, as β-arrestin-independent mechanisms have been
described158,261–263,

most

7TMRs

undergo

ligand-induced

endocytosis

through

β-

arrestin/dynamin/clathrin-coated-pits interactions, a 7TMR core process. Among 7TMR
subcellular trafficking regulators, the Ras-family small-GTPases Rab proteins are ubiquitous258,263.
In particular, Rab5 regulates endocytic/early endosomal processes, Rab4 and Rab11 control rapid
and slow recycling from recycling endosomes, Rab7 is a regulator of the late endosomes and the
lysosomal degradation pathway taken by ubiquitylated proteins. Localized throughout specific
intracellular stages, they can therefore serve as exploratory molecules to characterize GPCRs
trafficking pathways.
Rab proteins
Navigating through the ultra-dense network of actin fibers and microtubules necessitates the
guidance of proteins and cargoes to their appropriate destinations. These two last words suggest
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specific recognition and trajectories taken by the cargoes. This is accomplished by a set of proteins
counting around 60 subtypes: Rab proteins are small monomeric G proteins constituting the
largest group of the Ras-like protein superfamily and hold a common GTPase activity. They
orchestrate trafficking events between donor and target membranes. Each Rab protein is a
resident of the organelle membrane they regulate, providing an identity to the subcellular
compartment264. Organelles are also defined by specific scaffold proteins that anchor them to the
cytoskeleton, but also by the lipid composition of their membrane layers. Rab1 interacts with the
Golgi apparatus and the ER protein complexes each dedicated to their organelles functioning, to
activate the environing SNAREs, and to “read” compartments scaffolds to facilitate transport in
between the ER and the Golgi apparatus264.
The duration the GTPase activation cycle is regulated by guanine nucleotide exchange factor
(GEFs), who sustains the GDP/GTP exchange, and terminated by hydrolysis of GTP carried out
by GTPase activating proteins (GAPs). Rab proteins partner with Arf family to interact with the cell
cytoskeleton and in particular with the motor proteins that mediate the transportation of cargoes
along the microtubule/actin networks, in both directions265,266. For instance, Rab7a promotes the
trafficking of cargoes by recruiting the dynein/dynactin motor protein complex to the late
endosomes, to direct the enriched vesicles toward the perinuclear areas267. Similarly, Rab5 binds
to the early endosome antigen 1 protein (EEA1) to recruit the early endosome target, with
concomitant association to PI3P. Rab5 also recruit membrane effectors that allow interaction with
SNAREs for further engage membrane fusion268,269.
Rab proteins, besides providing identity and mobility to their respective organelles, can interact
with specific GEFs and GAPs of the next Rab protein, thus creating “Rab cascades” that will orient
and organize transitions between compartments. In particular, it has been proposed that Rab7 is
present on early Rab5 endosomes. Rab7 buds then grows on the Rab5 early endosome
membrane and likely interacts with converter proteins. These proteins would turn off the recycling
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properties of the sorting early endosomes (which are defined by Rab4 and Rab11), and convert it
to a late endosome270. Rab5 is displaced and Rab7 is activated. Because effector protein GEF
can recognize an increase in Rab5 and PIP3, this gives selectivity to the process. It is also
coincident with the membrane recruitment, therefore allowing Rab5 displacement toward Rab7 at
a specific time in a specific localtion271. This example demonstrates a mechanism that
synchronizes protein trafficking in time and space.
Considered as master regulators272, Rab proteins regulate vesicle sorting, docking, budding,
tethering and membrane fusion. They define the secretory and the endocytic routes by interacting
with specific components along these pathways. They also specify the microdomain occupied by
the organelle they control, underneath the plasma membrane. Rab proteins also regulate the
trafficking of 7TMRs, and it has been demonstrated that the basic four Rab proteins (4, 5, 7 and
11) direct and orient internalization and recycling of several 7TMRs273. Following β-arrestindependent desensitization after being internalize, 7TMRs follow multiple routes in accordance with
their interacting Rab protein, effector, or β-arrestin type. Indeed, it has been shown that 7TMRs
can follow two different arrestin-mediated pathways274. Following ligand-induced internalization,
β2AR has been shown to traffic through Rab5 endosomes275. Overstimulation of Rab5 by
expressing a dominant positive mutant affect β2AR trafficking through early endosomes.
Conversely, dominant negative Rab5 impairs early trafficking of the receptor. This was also the
case for the D2R, which is regulated by dynamin following phosphorylation by GRK2276.
Interestingly, the class A angiotensin receptor 1A (AT1AR) has been shown to use both β-arrestindependent and -independent pathways without being regulated by Rab5, although it is bound by
the receptor. This suggests that Rab5 mediates different endocytic mechanisms277.
Endosomes
Endosomes are dynamic cytoplasmic vesicles acting as trafficking regulators and sorting platform.
Their importance has generated much attention as targets for novel therapeutics 278,279. They
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provide the necessary space and means to regulate the trafficking, and identify not only the nature
of the entrant and recycled particles, endocytosed receptors and lipids, but also a platform for
receptor signaling, whether they come from the plasma membrane or from the secretory pathway.
They appear poorly studied despite their critical role in protein trafficking, as well as in receptor
signaling280.
Usually categorized as early (EE), sorting (SE), recycling (RE), or late endosomes (LE), they adopt
different shapes structured around the cytoskeleton with specific cellular functions. They can be
ramified to tubular extensions (EE, multi-vesicular body MVB) or simply remain spherical-like,
mostly depending on their function and associated motility, sustained over the microtubular
network281. The pH gradient between the cytoplasm and the lumen of intracellular vesicles
provides the differential ionic concentration that serves to dissociate the ligand from its receptor,
the former often directed to degradation whereas the latter can either been rerouted to the plasma
membrane or follows the same fate as its ligand282. The role of each endosome also depends on
their localization underneath the plasma membrane, constituting functional microdomains. Their
identity is determined by the combination of regulatory proteins and lipids that are unique to each
specialized endosome283.
A pH gradient spans through the cytoplasm from the plasma membrane to deeper compartments.
The higher pH is found right under the plasma membrane, where early endosomes control the
endocytic trafficking of newly endocytosed elements284 (recycling endosomes have a slightly
higher pH). They are thought to constitute the first and only entry point of endocytosed
proteins/lipids independently of the internalization mode, such as clathrin-mediated and lipid raftmediated endocytosis or pinocytosis, as well as the first recycling platform283,285. To that end, their
structure consists in several cisternal areas associated with budding vesicles and thin tubular
emanations (for a stunning visualization by electron microscopy of the EE structure see ref 283). A
complex association and interplay of specific resident proteins participate to endosomal transport,
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morphology, sequestration, docking, etc.283. Among them, Rab5 and its effectors appears to be
the main regulators that take on several functions such as spatial organization, docking affectation
from either trans-Golgi or plasma membrane. Membrane budding, fission and interaction with the
cytoskeletal components are also among Rab5 attributes (see above)268,286,287.
The model describing the compartmentalization of endosomes has been proposed by early
studies that investigated fluorescent markers routing and chased their cellular destination and
trafficking in a timely manner, usually depicting a common network of specialized vesicles as a
general trafficking model288. Although it was assumed that integral proteins, ion channels and
receptors underwent at least two types of internalization processes, degradation or recycling, the
putative motion of different membrane-based vesicles was described as a bulk flow process,
without specificity288. This model has been refined to the point that there is no longer such a bulk
flow of membranes that fusion and interact, but rather a complex interplay orchestrated by
specialized proteins and adaptors along endosomal-mediated tubular networks289, sorting motifs
attached to internalized cargoes that orient their route according to the cell needs290.
EE provide both fast and slow recycling pathways285, though evidence suggested that LE can also
recycle cargoes. Lumen pH is lower in LE, which link endocytosed cargoes to degradation
pathway through EE sorting284,291. Within the EE or the LE, cargoes routed to the recycling pathway
should avoid inclusion in intermediate degradative vesicles (intraluminal vesicles) to be able to
reach back to the plasma membrane, either by the slow or the fast recycling routes 290. Thus, LE,
also identified to MVB, function as sorting dispatchers290.
A major shift in envisioning receptor signaling was provided by findings in regard to intracellular
signaling, and more precisely, on signaling from endosomes. Receptor endocytosis has been
studied as a termination mechanism to regulate available receptor density at the cell surface and
mitigate cell responsiveness following agonist stimulation. Receptor desensitization and
resensitization are not general mechanisms that all 7TMRs undergo. Although β-arrestin30

dependent internalization of clathrin-coated pits and adapter protein-2 complex (AP-2), in
response to GRK-mediated receptor phosphorylation, plays a major role in 7TMR internalization,
besides being the most well characterized system, some receptor types are recycled, some are
not and get degradated292. Recycling endosomes employs several Rab proteins (Rab5, 4, and 11)
while late endosomes are often related to degradation pathways and mostly regulated by Rab7
(and Rab9). The early or sorting endosome is the first encountered container of most internalized
proteins and lipids285.
Together, this information suggests that the endosomal network is finely regulated by resident and
adaptor proteins, and that, together with the architecture of the specified endosomes, produces
subcellular microdomains composed by the vesicles tubular extensions over the actin/microtubule
skeleton293. Each microdomain, regulated by a specific Rab protein, serves as orientation
platforms to either degrade or recycle cargoes that are either endocytosed or synthetized.
Schizophrenia
Schizophrenia, or schizophrenia spectrum disorder (or syndrome), is a serious multifactorial
mental illness affecting up to 0.65% of the USA population and 20 million people worldwide294 (up
to 0.75%), with chronic, and in great majority, life-lasting social, emotional and cognitive
alterations. Clinical symptoms are often grouped as so-called negative, positive, and
cognitive295,296. Studies and definitions converge to acknowledge that a combination of genetic
susceptibilities and harmful environmental factors participate to its etiology, which remains
unknown. Nonetheless, despite a raise in the prevalence of brain disorders and consequent
increase economic and social burden297–300, where schizophrenia costs are disproportionately
high301, pharmacological companies have halted avenues of research for claimed financial
reasons302–308, creating a gap between a steady clinical and fundamental research and the
availability of commercialized medications.
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The classical hypothesis of dopaminergic hyperactivity gained attention since the antipsychotic
activity of several commercialized dopamine receptor (DR) antagonists (typical) would correct
some of the positive symptoms, especially delusions and hallucinations. The dopamine hypothesis
suggests that there is an imbalance of the dopaminergic tone in the prefrontal cortex that can be
rectified by treatment with D2R antagonists, such as chlorpromazine, pioneer molecule to treat
positive symptoms309. Compared to the first generation antipsychotics (the typical D2R/D3R
antagonists), atypical antipsychotics (AAP) have more affinity for the 5-HT2AR. Similarly, such
pharmacological evidence fashioned the serotonin hypothesis, also based on the resemblance
between serotonin receptor agonists that produce psychosis-like effects on humans. These
molecules exhibit substantial off target occupancy and are considered as “dirty drugs with rich
pharmacology”310, carrying at the same time, important side effects. They are yet prescribed as
first line compounds to treat schizophrenia’s positive symptoms, with moderate improvements of
negative and cognitive ones. A third of subjects do not respond to AAP311,312. Although the classical
theories on the onset and the etiology of the disorder remain up to date, the scope has yet evolved
toward other signaling pathways such as glutamate and GABA; the implication of a combination
of neurotransmitter systems rather than a single defective gene or pathway could shed light on
the disorder origin and mechansims309,313,314. Indeed, recent findings propose that a
heterogeneous genetic network causes distinct clinical syndromes315, as conveyed by years of
research on the implication of several genes that regulate and express 7TMRs, receptor trafficking
and neurotransmission, synaptic and structural plasticity316–320.
The variability of symptoms combined to the diversity of phenotypes resulting from clinical and
genetic observations conflict with a single disease paradigm, thus single medication are unlikely
to treat the full spectrum that characterize the disorder321. The absence of a uniform syndrome
renders difficult the delivery of accurate, specific and reproducible diagnostics322–325, which also
rely on definitions and clinical practices326. For instance, some criteria can overlap with those of
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bipolar disorder327 that may affect drug indication and assistance to patients328,329, who eventually
cope with long term/life lasting treatments, if they find access to them295,296.
It is nowadays a common concern as to challenge the single disease paradigm297,330, i.e. embrace
several theories about the disorder to provide novel and more efficient medications. This was the
case for atypical antipsychotics, who have affinity for both 5-HT2AR and D2R, and together increase
the beneficial effects on the disorder process and evolution, rather than just on symptoms 311,331–
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. The glutamatergic system has also gained in importance with the findings related to altered

NMDAR-mediated

glutamatergic

neurotransmission,

signaling

and

trafficking.

NMDAR

dysfunction on GABAergic neurons implicate a hyperglutamatergic stimulation responsible for
cognitive impairments and other deleterious effects found in schizophrenia. Agonizing the
mGluR/2/3 pathway potentially rectifies the glutamatergic overstimulation by reducing the
presynaptic release of glutamate on excitatory neurons, as a compensatory mechanism233. Those
agonists have been found to relieve all 3 symptoms type in patient with schizophrenia334. It was
believed that such molecules held a novel and promising mechanism of action that could be
beneficial to patients226,233.
Hypothesis
Investigations in post-mortem schizophrenic prefrontal cortexes suggested that 5-HT2AR specific
binding is increased yet rectified in treated subjects with AAPs. However, mGluR2 remained
downregulated in both untreated and treated schizophrenic subjects. We thus hypothesize that
biosynthesis and endocytosis of interacting 5-HT2AR and mGluR2 may play a role in their common
and linked dysregulation. Trafficking and signaling being entangled, endocytosis and biosynthesis
of 7TMR complexes control their cellular localization in time and space. Conversely, trafficking
failure implies signaling impairments, which eventually result in a host of pathologies. The
objective of the following study is to elucidate in in vitro and ex vivo models, the maturation and
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the ligand-dependent trafficking mechanisms regulating the 5-HT2AR-mGluR2 signaling complex
to further explicit the effect of their imbalance in schizophrenia.
Aims
Aim 1: 5-HT2AR modulates mGluR2 post-endocytic sorting. Hypothesis: Pharmacological
modulation of 5-HT2AR affects mGluR2 sorting and function through Rab-mediated trafficking
pathways.
Aim 2: Effects of 5-HT2AR antagonists/inverse agonists (antipsychotic) and hallucinogenic
agonists (propsychotic) on 5-HT2AR-mediated trafficking of mGluR2. Hypotheses: 5-HT2AR
and mGluR2 heterocomplex is affected by clozapine, as well as mGluR2 trafficking. Psychedelic
agents promote Rab5-dependent pathway of mGluR2, while non-psychedelic agents do not.
Aim 3: 5-HT2AR and mGluR2 are assembled as a GPCR complex in the biosynthetic
pathway. Hypothesis: 5-HT2AR and mGluR2 structurally associate in the biosynthetic pathway.
BiFC of 5-HT2AR and mGluR2 would be detected in both the endoplasmic reticulum and the Golgi
apparatus.
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Materials and Methods
Drugs
(±)-2,5-Dimethoxy-4-iodoamphetamine hydrochloride (DOI), 5-hydroxytrytamine hydrochloride (5HT; serotonin), Lysergic acid diethylamide (LSD), Ergotamine, GDP, and GTPγS were purchased
from Sigma-Aldrich. (1R,4R,5S,6R)-4-Amino-2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid
(LY379268), (2S)-2-amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid
(LY341495),
piperinemethanol

clozapine,
(M100907;

(R)-(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4MDL

100,907;

volinanserin),

3-[2-[4-(4-fluorobenzoyl)-1-

piperidinyl]ethyl]-2,3-dihydro-2-thioxo-4(1H)-quinazolinone hydrochloride (altanserin), L-glutamic
acid, 3-hydroxynaphthalene-2-carboxylic acid (3,4-dihydroxybenzylidene)hydrazide (dynasore),
[8β(S)]-9,10-didehydro-N-[1-(hydroxymethyl)propyl]-1,6-dimethylergoline-8-carboxamide maleate
(methysergide) and Lisuride were purchased from Tocris Bioscience. [3H]Ketanserin and
[35S]GTPγS were obtained from PerkinElmer Life and Analytical Sciences. [3H]LY341495 was
purchased from American Radiolabeled Chemicals. All other chemicals were obtained from
standard vendors.

Plasmid Construction
All PCR assays were performed with PfuUltra Hotstart Polymerase (Stratagene) in a Mastercycler
Ep Gradient Auto thermal cycler (Eppendorf). Cycling conditions were 30 cycles of 94C for 30 s,
55C for 30 s, and 72C for 1 min/kb of amplicon, with an initial denaturation/activation step at
94C for 2 min and a final extension step of 72C for 7 min. All the constructs were confirmed by
DNA sequencing. The following constructs have been previously described183,251,252: human 5HT2AR N-terminally tagged with the c-Myc epitope (pcDNA3.1-c-Myc-5-HT2AR), human 5-HT2AR
N-terminally tagged with the c-Myc epitope and C-terminally tagged with enhanced cyan
fluorescent protein (pcDNA3.1-c-Myc-5-HT2AR-eCFP), human 5-HT2AR N-terminally tagged with
the c-Myc epitope and C-terminally tagged with mCitrine (pcDNA3.1-c-Myc-5-HT2AR-mCitrine),
human 5-HT2AR N-terminally tagged with the c-Myc epitope and C-terminally tagged with mCherry
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(pcDNA3.1-c-Myc-5-HT2AR-mCherry), human 5-HT2AR N-terminally tagged with the c-Myc epitope
and C-terminally tagged with eYFP (pcDNA3.1-c-Myc 5-HT2AR-eYFP), human mGluR2 Cterminally tagged with eYFP (pcDNA3.1-mGluR2-eYFP), human mGluR2 C-terminally tagged with
eCFP (pcDNA3.1-mGluR2-eCFP), human mGluR3 C-terminally tagged with eYFP (pcDNA3.1mGluR3-eYFP), human mGluR2 with substitution of residues A6774.40, A6814.44 and A6854.48 in
mGluR2 for S6864.40, F6904.44 and G6944.48 in mGluR3 C-terminally tagged with eYFP (pcDNA3.1mGluR2TM4; formerly named pcDNA3.1-mGluR2TM4N). The construct 5-HT2AR-eCFP was
subcloned into the vector pcDNA5/FRT/TO (Invitrogen) for the subsequent generation of Flp-In TREx HEK293 cells, as we have previously reported335. For BiFC studies, constructs were
generated by subcloning the sequence encoding the N-terminal 172-amino acid fragment (mCiN172) or the C-terminal 67 amino acid fragment of mCitrine (mCi-C76), as we have previously
described [see

40

]. The constructs pcDNA3.1-mCi-N172, pcDNA3.1-mCi-C67, pcDNA3.1-

mGluR2-mCi-N172 and pcDNA3.1-mGluR2-mCi-C67 have been previously described251. The
form of 5-HT2AR C-terminally tagged with eCFP was digested with NheI and BamHI and subcloned
into the same restriction sites of pcDNA3.1-mCi-N172 and pcDNA3.1-mCi-C67 to generate
pcDNA3.1-5-HT2AR-mCi-N172 and pcDNA3.1-5-HT2AR-mCi-C67. The chimeric Gα protein Gαqi9
has been previously reported336. FRET calibration was performed on parental HEK293 cells
transfected with either pcDNA3.1-eCFP, pcDNA3.1-eYFP, or the tandem plasmid pcDNA3.1eCFP-eYFP.

Transient Transfection of HEK293 cells
Human embryonic kidney (HEK293) cells (ATCC: CRL-1573) were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% (v/v) dialyzed fetal bovine serum
(dFBS) and 1% penicillin/streptomycin (Gibco) in a 5% CO2 humidified atmosphere. Transfection
was performed using polyethylenimine (PEI) linear MW 2,500 (Polysciences), following standard
protocols.
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Generation of Stable Flp-In T-REx HEK293 cell lines
Generation Flp-In T-REx HEK293 cells expressing c-Myc-5-HT2AR-eCFP in an inducible manner
was preformed following standard protocols337. Briefly, Flp-In T-REx HEK293 cells were
transfected with a mixture containing either c-Myc-5-HT2AR-eCFP cDNA in the pcDNA5/FRT/TO
vector and pOG44 vector (1:9) using Lipofectamine 2000 reagent (Invitrogen), according to the
manufacturer’s instructions. When cotransfected with the pcDNA5/FRT/TO plasmid into the FlpIn mammalian host cell line, the Flp recombinase expressed from pOG44 mediates integration of
the pcDNA5/FRT/TO vector containing the gene of interest into the genome through Flp
recombination target (FRT) sites. Clones resistant to blasticidin (5.0 µg/ml; InvivoGen) and
hygromycin (2.2 µg/ml; InvivoGen) and expressing the Tet repressor (tetR) along with the inserted
c-Myc-5-HT2AR-eCFP at the FRT site were screened for eCFP expression by standard
fluorescence microscopy protocols.
Double stable cell lines expressing mGluR2-eYFP, mGluR3-eYFP or mGluR2TM4 constitutively
and 5-HT2AR-eCFP in an inducible manner were generated from the Flp-In T-REx HEK293 cells
described above. Cells were transfected using Lipofectamine 2000 reagent (Invitrogen) with the
vectors containing mGluR2-eYFP, mGluR3-eYFP or mGluR2TM4. Following transfection, cells
were selected for resistance to Geneticin (1 mg/ml; Invitrogen), and the resistant clones were
screened for receptor expression by standard fluorescence microscopy. Flp-In T-REx HEK293
cells stably expressing -opioid receptor tagged with eYFP and able to express c-Myc-5-HT2AReCFP in an inducible manner have previously been described335. To induce expression of 5HT2AR-eCFP, cells were treated with doxycycline (DOX) (1.0 µg/ml; 24 – 48 h). Dialyzed FBS was
used for cell growth to avoid activation of 5-HT2AR by 5-HT that is routinely present in serum.

Mice
5-HT2AR knockout (Htr2a-/-) mice of 129S6/Sv background have previously been described140. For
experiments involving 5-HT2AR-/- mice, wild-type (5-HT2AR+/+) littermates on a 129S6/Sv
background were used as controls. Animals were housed at 12 h light/dark cycle at 23C with food
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and water ad libitum. The Institutional Animal Use and Care Committee at Virginia Commonwealth
University School of Medicine approved all the experimental procedures.

Cortical primary cultures
Fetuses (E17-18.5) from pregnant mothers were removed using aseptic techniques. Cortical
primary cultures were performed as previously reported140. Cells were maintained for 7 days in
vitro before use in experiments.

Immunocytochemistry
In HEK293 cells or mouse cortical primary cultures, immunocytochemical assays were performed
as previously reported with minor modifications183,251,252. Briefly, cells were fixed with 4%
paraformaldehyde (Sigma) supplemented with 100 μM CaCl2 and 100 μM MgCl2 for 10 min at
room temperature, rinsed with PBS, and washed twice with PBS supplemented with 20 mM
glycine. Coverslips were incubated with 0.2% Triton X-100 for 10 min at room temperature and
incubated in the dark for 60 min with PBS containing 5% donkey or goat serum (according to the
secondary antibody). Primary antibody was added (40 µl on each coverslip) and incubated
overnight at 4C. Primary antibodies used were rabbit anti-c-Myc (Cell Signaling Technology
catalog no. 2272; diluted at 1:250), mouse anti-mGluR2 (Abcam catalog no. 15672; diluted at 6.5
µg/ml), goat anti-Rab5 (SICGEN catalog no. ab1024; diluted at 6.5 µg/ml [HEK293 cells] or 5.0
µg/ml [primary neurons]), rabbit anti-Rab7 (Cell Signaling Technology catalog no. 9367; diluted at
1:100), or rabbit anti-GFP (Invitrogen catalog no. A11122; diluted at 1:500) After washing with
PBS, cells were incubated for 60 min at room temperature in the dark with the secondary
antibodies Alexa Fluor 488-conjugated goat anti-rabbit (Invitrogen catalog no. A11011; dilution
1:1000), Alexa Fluor 568 conjugated goat anti-rabbit (Invitrogen catalog no. A11004; dilution
1:1000), Alexa Fluor 568-conjugated donkey anti-goat (Invitrogen catalog no. A11057; dilution
1:1000), or Dylight 650-conjugated donkey anti-mouse (Thermofisher catalog no. SA5-10169
[primary neurons]). For the maturation pathway: ER-Tracker Red (ER-Tr) dying protocol fits mostly
manufacturer’s recommendations (Thermofisher). Concentration was adjusted to 0.5µM of dye in
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pre-heated HBSS (Gibco), cells were incubated for 20 minutes in the same conditions as above
then fixed with 3% PFA during 2 minutes. For Golgi experiments, fixed cells were permeabilized
in a 0.2% Triton X-100/PBS solution then disposed in a PBS/3%FBS/1%BSA blocking solution.
Coverslips were then incubated for 60 minutes with 5µg/mL mouse anti-58K primary antibody
(Abcam), followed by 50 minutes in 0.5µg/mL conjugated AlexaFluor568 goat anti-mouse IgG
secondary antibody (Invitrogen). Nuclei were stained (5 min) with Hoechst 33342
(ThermoScientific). After washing (PBS, 6  5 min), the coverslips were mounted on glass slides
with Prolong Diamond Antifade Mountant (ThermoFisher).

Confocal microscopy
Fixed cells and living cells were visualized on a Carl Zeiss Axio Observer LSM 710 laser scanning
confocal microscope (LSCM) with a Plan-Apochromat 63/1.40 Oil DIC M27 or 40 Cal objective.
Hoechst 33342 was excited by a 405 nm blue diode, and eCFP with a 440 nm laser-pulse.
Additionally, 488 nm and 514 nm multi-line Argon lasers were used to excite Alexa Fluor 488,
mCitrine and eYFP, respectively, whereas a 561 nm green diode laser was used to excite mCherry
and Alexa Fluor 568. Finally, DyLight 650 was excited with a 633 nm HeNe laser line. Emission
signals were acquired in the same order using the following Main Beam Splitter/Dichroic Beam
Splitter (MBS/DBS) and emission filters (EF) sets: InVis 405/Mirror EF: 410-482nm, InVis
445/Mirror EF: 435-480 nm, 488/Mirror EF: 494-523 nm, 458/514/Mirror EF: 523-543 nm, and
458/561/633/Mirror EF: 591-661 (mCherry) 573-620 (AF568) 654-700 (DyLight650). Pinhole was
kept constant and adjusted at 1 airy unit. Living cells (cell cloning) were visualized on a Carl Zeiss
Cell Axio Observer Z1 spinning disc confocal microscope (SDCM) with an embedded Yokogawa
CSU-X1 spinning disc and a C-Apochromat 63/1.20 W Korr UV-Vis-IR objective. Illumination
sources were a 458 nm and 514 nm (multi-Ar) laser for eCFP and eYFP, respectively. Emission
filters (SD mirror + bypass filters BP) were RTFT457/514/647 + BP485/30 (eCFP) and
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RQFF405/488/568/647 + BP525/50 (eYFP). During image acquisition, cells were maintained at
37°C and 5% CO2 atmosphere by an incubation system.

Immunoblot Assays
Western blot experiments were performed as previously reported252, using rabbit anti-c-Myc (Cell
Signaling, catalog no. 2272; diluted at 1:400) and rabbit anti--actin (Abcam catalog no. 8227;
diluted at 0.33 µg/ml).

TAT-fused transmembrane domain interference peptides
Peptides derived from human mGluR2 TM4 and TM1 were custom synthesized (Genemed
Synthesis, Inc.). TAT (trans-activating transcriptional activator from human immunodeficiency
virus; YGRKKRRQRRR) was fused to the N-terminus of the human mGluR2 TM4
(YGRKKRRQRRRSPASQVAICLALISGQLLIVVAWLVVE) and TM1 (AWAVGPVTIACLGALATLFVLGVFVRHYGRKKRRQRRR) to obtain the correct orientation for the inserted peptide
because TAT binds to phosphatidylinosityol-(4,5)-biphosphate found on the inner surface of the
membrane338. TAT-labelled 38-mer peptide was used as an internal control (YGRKKRRQRRRVIAPLYTSCVNWQIF-VISMYRGARVAI). Stock solutions of the TAT-tagged peptides (5.2 mM)
were prepared in DMSO supplemented with glacial acetic acid (1.93%). For FRET assays, cells
were incubated with TAT-tagged peptides (10 µM, final concentration) for 60 min (DMSO’s final
concentration = 0.18%). For studies involving receptor agonists, TAT-tagged peptides were added
5 minutes before DOI or LY379269, or vehicle administration. For studies involving overnight
treatment with clozapine, TAT-tagged peptides were added both 5 minutes before clozapine or
vehicle administration and 65 minutes before cell fixation.

Proximity Ligation Assay
Heteromers of c-Myc-5-HT2AR-eCFP and mGluR2-eYFP were detected using the Duolink In Situ
PLA Detection Reagents Red technology kit (Sigma-Aldrich). Briefly, coverslips with fixed cells
were incubated with 0.1% Triton X-100 for 10 min at room temperature then in blocking solution
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according to manufacturer’s instructions. Cells were incubated overnight at 4°C with a mixture of
the primary antibodies (rabbit anti-c-Myc [Cell Signaling Technology, catalog no. 2272; 1:250],
and mouse anti-mGluR2 [Abcam, catalog no. 15672; 1:200]). Samples were incubated with
Duolink In Situ PLA Probe Anti-Rabbit PLUS Affinity purified Donkey anti-Rabbit IgG and Duolink
In Situ PLA Probe Anti-Mouse MINUS Affinity purified Donkey anti-Mouse IgG. Samples were
processed for ligation and amplification and were mounted onto glass slides with Prolong Diamond
Mountant. Z-stack images were acquired in a Carl Zeiss Axio Observer LSM 710 laser scanning
confocal microscope with a Plan-Apochromat 63/1.40 Oil DIC M27 objective (to obtain a
representative image) or 40 Cal objective (for quantification purposes). For each field of view, a
stack of three channels (one per staining) was obtained. Images were processed with Fiji software
version 2.0.0 (National Institutes of Health, Bethesda, MD). To quantify PLA signal, PLA-red
channel remained hidden during cell identification process. Automated counting involved selection
and cropping of each region of interest, Z-Stack projection of the PLA channel, subtraction of
background with a rolling ball radius of 20 pixels and finding maxima with a noise tolerance value
of 6000–10000 depending on the experiment and the background.

Radioligand binding assays
[3H]Ketanserin, [3H]LY341495 and [35S]GTPS binding assays were performed as previously
reported183,251,252. The stoichiometry of 5-HT2AR density (as assessed by [3H]ketanserin binding)
and mGluR2 density (as assessed by [3H]LY341495 binding) is similar to that previously observed
in native tissue, such as mouse frontal cortex and postmortem human frontal cortex183,251,252 and
in cross-talk positive clones254.

[Ca2+]i Mobilization assays
Two days before the assay, cells were plated onto poly-D-lysine coated 96-well plates (Greiner
Bio-One GmbH) and, 48 hours later, treated with doxycycline (1 µM) for 40 h. Cells were washed
with DPBS and loaded with 3 µM Fura 2-AM (Molecular Probes) in imaging solution (5 mM KCl,
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0.4 mM KH2PO4, 138 mM NaCl, 0.3 mM Na2HPO4, 2 mM CaCl2, 1 mM MgCl2, 6 mM glucose, 20
mM HEPES, pH 7.4) supplemented with pluronic acid (20% solution in DMSO). After incubation
for 30 min at 37°C, cells were washed twice with washing buffer before being placed on the
FlexStation 3 microplate reader (Molecular Devices). The Fura-2 signal was acquired at 510 nm
by switching the excitation wavelength between 340/380 nm. Intracellular calcium concentration
was expressed as a 340/380 nm ratio, and values were normalized to the basal 340/380 nm ratio
recorded during 30 seconds before perfusion of the drug using Softmax Pro (Molecular Devices).
To allow efficient coupling of Gi/o-coupled mGluRs to the PLC pathway, cells were also
transfected with the chimeric G protein Gqi9336. Concentrations of LY379268 were selected
based on our previous findings251. Thus, activation of the canonical Gi/o protein-dependent
pathway was tested in the presence of LY379268 (0.1 µM), but trans-activation of the Gq/11
protein-dependent pathway was tested in the presence of LY379268 (10 µM and 100 µM).

Flow cytometry and immunofluorescence
Cells were treated with for 60 min with either DOI (1 µM), LY379268 (10 µM), or vehicle, or
(overnight) with clozapine (10 µM) M100907 (10 µM) or vehicle. Cells were trypsinized, washed
with PBS, filtered through filter top tubes (35 µm), resuspended in PBS supplemented with 1%
FBS, and analyzed using a LSRFortessa X-20 Flow cytometer (BD Bioscience). eCFP and eYFP
were excited with a 405 nm and a 488 nm laser line, respectively. Emission filters were 525/50
and YFP-A. Quantification was carried out using FCS Express v.5 (De Novo Software). Mean
intensity values were determined by gating 25.5% or more of the total cell population. Imaging
flow cytometry (Amnis ImageStreamX) to measure colocalization of mGluR2 or 5-HT2AR with the
transferrin receptor at the single cell level was performed as previously reported, using an Amnis
ImageStream flow cytometer254. Cells were considered to present a colocalized signal between
the receptor constructs and transferrin receptor when their Bright Detail Similarity score was
greater than 2. To detect cell surface receptors, cells were treated with DOI, LY379268 or vehicle
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(60-min treatment), or with clozapine, M100907 or vehicle (overnight treatment). Cells were
washed with ice-cold imaging buffer (PBS supplemented with 10% FBS) and incubated with
human mGluR2 Alexa Fluor 647-conjugated antibody (R&D Systems, catalog no. IC4676R; 1:40)
for 60 min on ice (~11-13°C). After two washes with ice-cold imaging buffer, cells were
resuspended in ice-cold imaging buffer and loaded into the flow cytometer. 405 nm, 488 nm and
640 nm lasers were used to excite eCFP, eYFP and AF647, respectively. Data were subsequently
gated and analyzed using the FCS Express 5 software. For the maturation pathway: IFC assays
were performed on the Amnis ImageStreamX Mark II flow cytometer (IS). Prior to analysis, probefree cells and single color channels controls were made in order to evaluate background
autofluorescence and to set the compensation matrix parameters required to separate spectral
overlap of fluorescent probes. For BiFC experiments, cells were transfected 24h before
experiment on 10 cm plates using scaled up DNA/PEI concentrations. mCitrine and ER-Tr were
illuminated with a 488 nm and a 561 nm lasers respectively. In-focused cells were acquired with
a 60x objective and gated by gradients MAX and RMS controlling bright field focus quality, then
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score is then determined and set to gate and identify highly colocalized populations254. BDS is a
log-transformed Pearson Correlation Coefficient.

SensorFRET
SensorFRET assays were performed as previously reported339. Briefly, the fluorophores
associated with uneven expression levels between the donor and acceptor. The fluorophores used
as the FRET pair were eCFP (donor) and eYFP (acceptor) with quantum yields assumed to be
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0.40 and 0.61, respectively340. This approach also requires knowledge of the fluorophore emission
shapes (for linear unmixing of the spectra) as well as the relative molar extinction coefficients for
the fluorophores at each excitation frequency (characterized by the  parameter). The normalized
emission shapes of both fluorophores as well as the autofluorescence at each excitation frequency
were determined experimentally. The γ calibration term was also determined experimentally ( =
0.114), following a previously described procedure339. Imaging was carried out using a Zeiss 710
confocal LSM at 405nm and 458 nm excitation frequencies and a 32-channel spectral detector
spanning an emission range of 416nm to 718nm. In unfixed cells, short acquisition times (~ 600
ms) were necessary to minimize the shift due to vesicle movement during the time needed to
acquire images at both excitation wavelengths. For assays involving TAT-tagged peptides, cells
were briefly fixed with PFA (1%) for 5 min to avoid background caused by PFA fixation. A minimum
of 30 cells were imaged for each experimental group. For the statistical analysis, the measured
FRET efficiency of each vesicle was considered a single observation. Strict masking was carried
out to include vesicles that met three criteria. First, only vesicles which remained stationary
between the 405 and 458 nm images were included because even at short acquisition times, some
population of vesicles showed appreciable movement. Second, only vesicles with a donor to
acceptor stoichiometry within the range of 1:10 to 1:1 were included because the sensorFRET
approach is not applicable when there are excess donor fluorophores339. Thus, below a 1:10 ratio
the donor signal is so small that it is difficult to reliably distinguish it from auto fluorescence and
noise. The stoichiometry was estimated by comparing the ratio of the donor and acceptor direct
excitation in experimental vesicles to a unimolecular construct (both CFP and YFP are encoded
as part of the same protein) where the stoichiometry is known to be 1:1. Marks were drawn only
over pixels that showed colocalized eCFP and eYFP signal from both 405 nm and 458 nm images.
Finally, only vesicles consisting of greater than 5 pixels were included so that mis-localization of
proteins to small non-vesicle features was excluded, allowing each vesicle observation to be the
average of multiple spectra and improving the signal to noise ratio.
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Electron Microscopy
Electron microscopy assays were carried out as previously reported with minor modifications252.
Briefly, four male mice (8 – 12 weeks old) per genotype were deeply anesthetized and perfused
transcardially with 2% dextran (MW 70,000) in 0.1 M phosphate buffer (PB, pH 7.4), and then with
a mixture of 4% paraformaldehyde and 0.125% glutaraldehyde in phosphate buffered saline
(PBS). Brains were removed and post-fixed in the same perfusate overnight at 4°C. Approximately
0.5-mm-thick coronal slices were dissected from the regions of interest. Tissue blocks through
superficial layers of prefrontal cortex were embedded in Lowicryl HM20 resin (Electron Microscopy
Sciences, Fort Washington, PA) by freeze substitution and low-temperature embedding of the
specimens using methods previously described341–343. Briefly, slices were cryoprotected by
immersion in 4% D-glucose, followed with increasing concentrations of glycerol (from 10% to 30%
PB). Sections were plunged rapidly into liquid propane cooled by liquid nitrogen (−190°C) in a
Universal Cryofixation System KF80 (Reichert-Jung, Vienna, Austria). The samples were
immersed in 0.5% uranyl acetate dissolved in anhydrous methanol (−90°C, 24 h) in a
cryosubstitution AFS unit (Leica, Vienna, Austria). The temperature was raised from −90°C to
−45°C in steps of 4°C/h. After washing with anhydrous methanol, the samples were infiltrated with
Lowicryl HM20 resin at −45°C. Polymerization with ultraviolet light (360 nm) was performed for 48
h at −45°C, followed by 24 h at 0°C. Ultrathin sections (80 nm) were cut using a diamond knife on
a Leica UC7 ultramicrotome, and mounted on 300 mesh nickel grids (EMS) coated using a CoatQuick adhesive pen (EMS). Grids with sections were incubated in 0.1% sodium borohydride and
50 mM glycine for 6 minutes at room temperature, washed and incubated for 10 min in Trisbuffered saline with 0.1% Triton X-100 (TBST) containing 2% albumin. For immunolabeling,
sections were incubated overnight in primary anti-mGluR2 antibody (Abcam, mouse monoclonal
antibody catalog no. 15672, 10 µg/ml) in the same diluent as above, washed with TBST, and
incubated with secondary anti-goat 10 nm gold-tagged antibody (EMS; 1:20) in TBST (2% albumin
and polyethyleneglycol 20,000; 5 mg/ml) for two hours, washed and counter-stained with 1%
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uranyl acetate (aq.). The specificity of the primary antibody against mGluR2 was previously
confirmed in experiments with knockout mice252. Grids were viewed on a Hitachi 7000
transmission electron microscope and imaged at a final captured image magnification of 130K.
Imaging concentrated on deep layer 2-3 of the prefrontal cortex. Excitatory (asymmetric)
glutamatergic synapses were identified by the presence of a thickened postsynaptic density,
synaptic cleft, and clusters of round presynaptic vesicles344. A synapse was scored as
immunolabel-positive if it contained at least 3 gold particles in the synaptic compartments
described above, and 25-35 labeled synapses were imaged per animal/group. Overall, ~90% of
labeled synapses showed gold particles associated within the postsynaptic element, though a
small population of synapses contained gold particles limited to its presynaptic compartment. Gold
particle distribution with respect to plasmalemma was scored for each postsynaptic site as
membrane only, intracellular only, or both. Membrane labelling was defined by gold particles falling
within 25 n of the plasmalemma (a distance defined by the approximate size of the primary and
secondary antibodies).

Data acquisition and statistical analysis
Statistical

analysis

was

performed

with

a

GraphPad

Prism

software

version

8.

Immunocytochemical assays were acquired using confocal fluorescence microscopy at identical
settings for each of the experimental conditions. For colocalization assays, raw 16-bit image files
(.czi) were imported into the Carl Zeiss ZEN software (Black version) and/or Fiji version 2.0.0 with
Coloc 2 plugin. To assess colocalization, Pearson’s and/or Manders’ coefficients were calculated
because these colocalization coefficients are based on pixel-intensity-correlation measurement
and do not include object-recognition approaches. Pearson’s coefficient, which ranges from +1
(total positive linear correlation) to -1 (total negative correlation; 0 defines absence of linear
correlation) is sensitive to both signal cooccurrence and the more rigorous condition of signal
correlation (pixel-for-pixel proportionality in the signal levels of the two channels). However, unlike
Pearson’s correlation coefficient, Manders’ fractional overlap coefficients (M1 and M2), which
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measure the fraction of a probe in a probe-tagged compartment and range from 0 (no overlap) to
1 (perfect overlap), strictly measures co-occurrence independent of signal proportionality345,346.
Colocalization of two fluorescently labelled 7TMR constructs (5-HT2AR-eCFP and mGluR2-eYFP)
was assessed both by Manders’ and Pearson’s coefficients, whereas colocalization of a
fluorescently labelled 7TMR construct with a marker of endosomal vesicles (Rab5) was assessed
by Manders’ coefficient. Both Manders’ and Pearson’s coefficients within the region of interest
were calculated after setting single color thresholds by either colocalizing single probe channels
or manually defining a threshold mask upon background subtraction in all channels using Rolling
Ball Radius of the largest object in the image (~ 20 – 30 µm). Colocalization was scored in at least
25 cells per experimental condition in three independent assays where the experimenter was
blinded to the experimental conditions. For Manders’ and Pearson’s coefficients, cell regions of
interest were demarcated according to the eYFP signal located at the plasma membrane as a
potential cell surface marker. For FRET signal, pixels of interest were demarcated based on their
intracellular colocalization of eCFP and eYFP signal. For PLA signal, cell regions of interest were
demarcated according to eYFP signal within previously defined eCFP-positive cells. For
intracellular eYFP signal, cell regions of interest were randomly demarcated based on eCFP signal
within intracellular vesicles. Signal intensity for intracellular eYFP was assessed with the Carl
Zeiss ZEN software (Black version). The laser intensity was kept constant among all experimental
conditions. Straight-line selections were drawn from the plasma membrane to the nucleus or
across the cytoplasm, and pixel intensities across the line were measured using plot profile in Fiji.
Pixels with maximum and minimum intensities were normalized to 100 and 0, respectively. The
statistical significance of experiments involving three or more groups and two or more treatments
was assessed by two-way ANOVA followed by Bonferroni’s post hoc test. Statistical analysis of
experiments involving three or more groups was assessed by one-way ANOVA followed by
Bonferroni’s post hoc test. Statistical analysis involving two groups was assessed by Student’s ttest. For FRET analysis, statistical analysis was assessed by Mann-Whitney U test or one-way
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non-parametric ANOVA (Kruskal-Wallis) with Dunn’s post hoc test because FRET datasets show
a Cauchy distribution with heavier tails. Normality and homoscedasticity assumptions were
checked prior to any calculation. Radioligand binding saturation curves were analyzed using a
nonlinear curve fitting approach. An extra-sum-of-squares (F test) was used to determine
statistical significance for simultaneous analysis of binding saturation curves and [35S]GTPS
binding assays. The level of significance was set at P = 0.05. Values included in the figure legends
represent mean  SEM, except for FRET assays where figure legends represent median with 95%
confidence interval.

48

Results
I. Cellular distribution of mGluR2 and 5-HT2AR alone and together in HEK293 cells
1. 5-HT2AR distribution pattern in HEK293 cells
To first determine and compare expression patterns of human mGlu2 and 5-HT2A receptors in a
heterologous cellular system and to validate previous findings showing an elevated intracellular
localization of the 5-HT2AR, we introduced the mCitrine sequence at the C-terminus to generate
5-HT2AR-mCitrine. As shown before251,347, HEK293 cells transfected with the 5-HT2AR-mCitrine
exhibit a fluorescent signal mostly localized in intracellular vesicles (Fig. 1A). To rule out a direct
effect of the C-terminally tagged mCitrine on receptor trafficking, we used a second method where
the epitope c-Myc was tagged to the N-terminus of the 5-HT2AR construct. Similar to the
distribution pattern observed with 5-HT2AR-mCitrine, the c-Myc-5-HT2AR construct was primarily
located intracellularly (Fig. 1B).
2. Cotransfection of 5-HT2AR and mGluR2
mGlu2 receptor exhibits a standard surface receptor distribution where most of the expression is
visible at the plasma membrane area (Fig. 1C). However, when 5-HT2AR and mGluR2 constructs
were co-transfected, mGluR2 pattern of expression was dramatically changed. In contrast to the
subcellular localization observed in HEK293 cells transfected with the mGluR2-mCitrine construct
alone, coexpression of 5-HT2AR-mCherry led to the partial internalization of mGluR2-mCitrine
(Figs. 1, D and E), which can also be demonstrated by a high level of colocalization of mGluR2mCitrine and 5-HT2AR-mCherry in intracellular vesicles (Fig. 1F). Additionally, not all the
cotransfected cells exhibited the observed relocalization of mGluR2, not in the same proportion.
This suggests that the stoichiometry can affect the change responsible for the mGluR2 subcellular
distribution.
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Fig. 1. 5-HT2AR affects localization of mGluR2. (A and B) Representative confocal micrographs
of HEK293 cells transfected to express 5-HT2AR-mCitrine (A) or c-Myc-5-HT2AR (B).
Nonpermeabilized cells were imaged to detect mCitrine (A), whereas permeabilized cells were
stained with anti-c-Myc and secondary antibody, and imaged to detect anti-c-Myc (B). (C to E)
HEK293 cells were transfected to express mGluR2-mCitrine alone (C), 5-HT2AR-mCherry alone
(D), or 5-HT2AR-mCherry and mGluR2-mCitrine (E). (F) Representative line scan. (G) BiFC signal
in HEK293 cells transfected to coexpress 5-HT2AR-mCi-N172 and 5-HT2AR-mCi-C67, mGluR2mCi-N172 and mGluR2-mCi-C67, or 5-HT2AR-mCi-N172 and mGluR2-mCi-C67. (H and I)
Representative micrographs of BiFC controls. HEK293 cells co-transfected to express mCi-N172
and mCi-C67 (probes only) and submitted to immunofluorescence assay using antibody against
GFP conjugated to a fluorescent secondary antibody (H). Absence of mCitrine signal when cells
were cotransfected either with both 5-HT2AR-mCi-N172 and mCi-C67 or with both mGluR2-mCiN172 and mCi-C67 (I). Nuclei were stained in blue with Hoechst. Scale bars, 5 µm.
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II. Intracellular localization of the 5-HT2AR-mGluR2 heterocomplex
1. Intracellular complementation of 5-HT2A and mGluR2
The 5-HT2A-mGluR2 receptor heteromer study resembles a niche in the field of 7TMRs oligomers.
Our laboratory has become an expert in the study of the structure and function of this
heterocomplex. We thus expected to locate it at the cell boundaries, using several RRI assays.
To track the intracellular physical interaction between 5-HT2AR and mGluR2 in HEK293 cells, we
used bimolecular fluorescence complementation (BiFC) as a biophysical technique that allows
visualization of protein complexes in transfected mammalian cells348,349. BiFC enables generation
of a single fluorescent signal when each of the constructs fused to a fragment of the mCitrine
fluorescent protein interact. The recovery of the protein quaternary structure attests the interaction
between the two proteins. BiFC signal was detected in cells cotransfected with 5-HT2AR fused to
either the N-terminal 172 amino acid fragment or the C-terminal 67 amino acid fragment of
mCitrine (mCi-N172 and mCi-C67, respectively) (Fig. 1G), which further corroborates the
capability of 5-HT2AR to form a family A GPCR homodimer165. Additionally, BiFC signal in cells
coexpressing 5-HT2AR-mCi-N172 and 5-HT2AR-mCi-C67 was observed intracellularly (Fig. 1G),
whereas BiFC signal in cells coexpressing mGluR2-mCi-N172 and mGluR2-mCi-C67 was mostly
detected at the plasma membrane (Fig. 1G). Importantly, this pattern of BiFC signal was
redistributed in cells coexpressing 5-HT2AR-mCi-N172 and mGluR2-mCi-C67 (Fig. 1G), which
suggests that physical interaction between 5-HT2AR and mGluR2 can be detected both close to
the cell surface as well as intracellularly. Internal controls to validate BiFC signal specificity
included cotransfection of themCi-N172 and mCi-C67 constructs (Fig. 1H), as well as mCi-C67
and 5-HT2AR-mCi-N172, or mCi-C67 and mGluR2-mCi-N172 (Fig. 1I).

52

III. GPCR heteromerization is necessary for the 5-HT2AR-mediated mGluR2 internal
relocalization
The use of stable cellular systems as a reductionist approach to observe trafficking events after
receptor activation was chosen as a model for this study. This choice has several advantages,
including overcoming expression variability and transfection efficiency issues – it is easy to
routinely grow, treat and analyze, and to manage the expression levels. To that purpose, we
devised an experimental Flp-In T-REx HEK293 cellular system that enables small molecule
doxycycline (DOX)-inducible expression of the inserted human HTR2A gene construct along with
the stable expression of mGlu2, mGlu3 or mGlu2ΔTM4 (see below) receptors. The Flp-In T-REx
system allows expression of the inserted construct into the cell genome via Flp-In recombinasemediated DNA recombination at the Flp recombination target (FRT) site, which can be controlled
by the incorporation DOX to the cell culture medium. This model of stable cell lines has already
been employed to great advantage in the study of receptor pharmacology, trafficking and
oligomerization45,335. Here we used Flp-In T-REx HEK293 cells to further explore the effect of 5HT2AR on subcellular localization of mGluR2.
The c-Myc-5-HT2AR-eCFP construct was inserted into the appropriate locus of the Flp-In
expression system, and pools of positive Flp-In T-REx HEK293 cells were selected. No visible
expression of the eCFP-tagged construct was observed in the absence of DOX (Fig. 2A).
However, presence of DOX resulted in expression of the integrated construct as monitored by
fluorescence corresponding to eCFP (Fig. 2B) and immunoblotting with anti-c-Myc antibody (Fig.
2C), which also serves as a concentration indicator of receptor expression. Induction of expression
of c-Myc-5-HT2AR-eCFP was concentration- and time-dependent, reaching maximal levels within
30 – 40 h upon 1 g/mL [DOX] administration (Figs. 2, B and C), and lasted a couple of days,
approximately. Additionally, as shown above in HEK293 cells transiently transfected with the 5HT2AR construct, visualization of living Flp-In T-REx HEK293 cells corroborated that the bulk of c53
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Fig. 2. Confocal micrographs of Flp-In T-REx HEK293 cells expressing the 5-HT2A receptor.
(A and B) Representative live-cell confocal micrographs of Flp-In T-REx HEK293 cells harboring cMyc-5-HT2AR-eCFP at the inducible locus. Cells were left untreated [DOX(-)] (A) or treated for 24h,
48h, or 72 h with doxycycline [DOX(+)] (B). (C) Membranes from Flp-In T-REx HEK293 cells
harboring c-Myc-5-HT2AR-eCFP at the inducible locus left untreated or treated with doxycycline at
the indicated concentration were immunoblotted with anti-c-Myc (upper panel) or anti--actin. Scale
bar, 5 µm.
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Myc-5-HT2AR-eCFP was located intracellularly (Fig. 2B). Those experiments generated a series
of parental clones expressing inducible 5-HT2AR.
In order to demonstrate the involvement of 7TMR heteromerization in the relocalization of mGluR2
following its coexpression with 5-HT2AR, we first based our negative controls with mGluR3 as well
as with an mGluR2/mGluR3 chimeric construct that does not form a receptor heteromer with 5HT2AR. We selected the mGluR2/mGluR3 chimeric construct mGluR2TM4 because, according
to previous findings from substitution of residues Ala-6774.40, Ala-6814.44 and Ala-6854.48 in mGluR2
for Ser-6864.40, Phe-6904.44 and Gly-6944.48 in mGluR3 decreases signal that indicates heteromeric
assembly. This was demonstrated based on the use of several independent experimental
approaches, including flow cytometry-based fluorescence energy resonance transfer (FCM-based
FRET), FRET microscopy, and coimmunoprecipitation in HEK293 cells251,252.
The parental c-Myc-5-HT2AR-eCFP expressing clones were then transfected with either mGluR2eYFP, mGluR3-eYFP or mGluR2TM4-eYFP, and individual clones constitutively eliciting eYFP
signal were selected. Visual inspection of eYFP fluorescence confirmed that, in the absence of
DOX, mGluR2-eYFP was localized at the cell boundaries (Fig. 3A). Remarkably, DOX-induced
expression of 5-HT2AR-eCFP dramatically affected the subcellular distribution of mGluR2-eYFP,
now partially internalized in vesicles (Fig. 3A). This effect of 5-HT2AR-eCFP expression was not
observed in cells stably expressing either mGluR3-eYFP (Fig. 3B) or mGluR2TM4-eYFP (Figs.
3C). Both mGluR3-eYFP and mGluR2TM4-eYFP showed a higher degree of intracellular
localization as compared to mGluR2-eYFP, yet both quantitative evaluation (Fig. 3D) and
representative line scans (Figs. 3, E to G) demonstrated significantly less subcellular proximity
between 5-HT2AR-eCFP and mGluR3-eYFP or mGluR2TM4-eYFP, as compared to the high
degree of overlap between 5-HT2AR-eCFP and mGluR2-eYFP. The subcellular distribution of the
class A Gαi/o protein-coupled -opioid receptor, which is a prototypical plasma membrane-
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Fig. 3. Effect of 5-HT2AR on localization of mGluR2 requires heteromerization. (A to I) Flp-In
T-REx HEK293 cells stably expressing mGluR2-eYFP (A, D and E), mGluR3-eYFP (B, D and F),
mGluR2TM4-eYFP (C, D and G), or OR-eYFP (H and I) and harboring 5-HT2AR-eCFP at the
inducible locus were untreated [DOX(-)] or treated with doxycycline [DOX(+)]. Representative
confocal micrographs (A to C and H) and corresponding line scans (E to G and I). (D) Manders’
and Pearson’s colocalization coefficients analysis of eYFP- and eCFP-tagged constructs (n = 25
– 33 cell regions of interest in three independent experiments). Data are mean  SEM (D).
Statistical analysis was performed using the one-way ANOVA (D) with Bonferroni’s post hoc test.
**P < 0.01, ***P < 0.001. Scale bars, 5 µm.
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localized 7TMR, was not evidently affected by DOX-induced expression of 5-HT2AR-eCFP (Figs.
3, H and I), further comforting the specificity of the relation between 5-HT2AR and mGluR2.

IV. Characterization of the double stable cells lines
Radioligand binding assays with the 5-HT2AR antagonist [3H]ketanserin confirmed that addition of
DOX resulted in 5-HT2AR-eCFP expression in cells stably expressing mGluR2-eYFP, mGluR3eYFP or mGluR2TM4-eYFP (Figs. 4, A to C, and Table 1). Using the mGluR2/3 antagonist
[3H]LY341495, we also observed that DOX-induced expression of 5-HT2AR-eCFP led to a
statistically significant increase in the density of mGluR2-eYFP, an effect that was not observed
in cells stably expressing mGluR3-eYFP or mGluR2TM4-eYFP (Figs. 4, D to F, and Table 1).
This effect of DOX-induced 5-HT2AR-eCFP expression on augmentation of mGluR2-eYFP density
was corroborated by fluorescence flow cytometry assays (Figs. 4, G and H).
We next assayed the effect of the mGluR2/3 agonist LY379268 on stimulation of [35S]GTPγS
binding as a functional readout of receptor-Gαi/o protein coupling. Interestingly, DOX-induced
expression of 5-HT2AR-eCFP reduced the functional properties of LY379268 augmenting
[35S]GTPγS binding in cells stably expressing mGluR2-eYFP (Fig. 4I), an allosteric event that was
absent in cells stably expressing mGluR2ΔTM4-eYFP (Fig. 4J). Although activation of mGluR2
elicited a robust G protein signal after ligand binding, we were unable to test mGluR3 function with
the [35S]GTPγS assay on clones stably expressing mGluR3. In order to overcome this issue, Gαi/ocoupled receptors mGluR (i.e., mGluR2, mGluR3 and mGluR2ΔTM4) ability to trigger the
phospholipase C pathway following activation of the G Protein, we transfect DOX(-) cells with the
chimeric G protein Gαqi9 and analyzed the fold increase in [Ca2+]i (Fig. 4K) following application of
0.1 μM of the mGluR2/3 agonist LY379268. Together with the effects of 5-HT2AR on mGluR2
subcellular redistribution (see above), these findings suggest that, although DOX-induced
expression of 5-HT2AR results in augmentation of total mGluR2 density, its functional properties
for agonist-induced Gαi/o protein recruitment are diminished.
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Activation of 5-HT2AR stimulates the β-isoforms of phospholipase C (PLC-β ) that catalyzes the
hydrolysis of phosphatidylinositol bisphosphate (PIP2), leading to the production of two second
messengers, namely inositol triphospate (IP3) and diacylglycerol (DAG). The Gαq-mediated signal
is then transmitted through to those molecules: IP3 binds to its ER localized receptor and open the
channel allowing mobilization of the internal store and efflux of calcium in the cytosol. DAG binds
to the plasma membrane to recruit the protein kinase C that is activated by Ca2+ and mediates
several other pathways. Our previous results suggested that stimulation of cells coexpressing
mGluR2 and 5-HT2AR with the mGluR2/3 selective agonist LY379268 leads to a Gαq/11 proteindependent increase in the concentration of [Ca2+]I251,253,254, a transactivation mechanism event that
has been validated by some170,350 but not all studies351.
Besides physically interacting, 5-HT2AR and mGluR2 have been shown to crosstalk by modulating
their respective G proteins signaling. The endogenous ligands serotonin and glutamate tend to
increase the Gαi signaling and reduce the Gαq signaling within the heterocomplex. Intracellular
calcium mobilization mediated by inositol 1,4,5-triphosphate from endoplasmic reticulum
compartments can be monitored by calcium-sensitive fluorescent dyes. The highly sensitive
ratiometric calcium dye Fura-2 was used to assess calcium elevation in our clones expressing
mGluR2 or mGluR2ΔTM4-eYFP along with the induction of 5-HT2AR expression. Application of 10
μM of LY379268 was sufficient to increase the intracellular calcium concentration in cells
expressing mGluR2, with a much lesser signal for the cells expressing the mutant receptor
mGlu2ΔTM4-eYFP. This effect seemed dose-dependent as with 100 μM an even greater signal
was observed (Figs. 4, L and M). As expected, neither serotonin (5-hydroxytryptamine, 5-HT) nor
LY379268 had such an effect on Ca2+ release in DOX(-) Flp-In T-REx HEK293 cells, whereas 5HT stimulated an increase in intracellular Ca2+ release in DOX(+) cells (Fig. 4N). An additional
internal control included absence of effect of 5-HT on Ca2+ release in untransfected HEK293 cells
(Fig. 4N). This findings indicate that we were able to reproduce the previous observed phenotype
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Fig. 4. Characterization of the double stable cells lines. (A to C) Density of 5-HT2AR as
measured by [3H]ketanserin binding in cell membrane preparations of Flp-In T-REx HEK293 cells
stably expressing mGluR2-eYFP (A), mGluR3-eYFP (B), or mGluR2TM4-eYFP (C) and
harboring 5-HT2AR-eCFP at the inducible locus. Cells were left untreated [DOX(-)] or treated with
doxycycline [DOX(+)] (representative results of three independent experiments performed in
duplicate; see also Table 1). (D to F) Density of mGluR2/3 shown as [3H]LY341495 binding in cell
membrane preparations of Flp-In T-REx HEK293 cells stably expressing mGluR2-eYFP (D),
mGluR3-eYFP (E), or mGluR2TM4-eYFP (F) and harboring 5-HT2AR-eCFP at the inducible
locus. Cells were untreated [DOX(-)] or treated with doxycycline [DOX(+)] (representative results
of three independent experiments performed in duplicate; see also Table 1). (G and H) Cells were
untreated [DOX(-)] or treated with doxycycline [DOX(+)], and densities of 5-HT2AR-eCFP and
mGluR2-eYFP with eCFP (G) and eYFP (H), respectively, were assessed by FACS assays (n =
10 independent experiments with 8459 – 9710 cells per experimental condition). (I and J) Effect
of the mGluR2/3 agonist LY379268 on [35S]GTPS binding in membrane preparations of Flp-In TREx HEK293 cells stably expressing mGluR2-eYFP (I) or mGluR2TM4-eYFP (J) and harboring
5-HT2AR-eCFP at the inducible locus. (K) [Ca2+]i mobilization of mGluRs clones by activation of
the chimeric Gα protein Gαqi9. Flp-In T-REx HEK293 cells stably expressing mGluR2-eYFP,
mGluR3-eYFP or mGluR2TM4-eYFP and harboring 5-HT2AR-eCFP at the inducible locus were
untreated [DOX(-)], loaded with Fura-2 and monitored for intracellular calcium concentration after
administration of LY379269 (0.1 µM), or vehicle. To allow efficient coupling of Gαi/o-coupled
receptors (mGluR2, mGluR3 and mGluR2TM4) to the PLC pathway, cells were also transfected
with the chimeric Gα protein Gαqi9. Analysis of the fold increase in [Ca2+]i (n = 4 independent
experiments, representative results of three independent experiments performed in duplicate). (L
and M) Flp-In T-REx HEK293 cells stably expressing mGluR2-eYFP or mGluR2TM4-eYFP and
harboring 5-HT2AR-eCFP at the inducible locus were untreated [DOX(-)] or treated with
doxycycline [DOX(+)], loaded with Fura-2 and monitored for intracellular calcium concentration
after sequential administration of LY341495 and/or LY379268, or vehicle. Representative time
course of Ca2+ release. The arrowhead indicates the time when drugs were added (M). Analysis
of the fold increase in intracellular calcium concentration (L; n = 4 – 8 independent experiments).
(N) [Ca2+]i mobilization of mGluRs clones expressing 5-HT2AR only, or untransfected HEK293
cells. Flp-In T-REx HEK293 cells stably expressing mGluR2-eYFP and harboring 5-HT2AR-eCFP
at the inducible locus or untransfected HEK293 cells were treated with doxycycline (or left
untreated), loaded with Fura-2 and monitored for intracellular calcium concentration after
administration of 5-HT (1 µM) or LY379268 (100 µM), or vehicle (n = 4 independent experiments).
Data are mean  SEM (D, I, J, K, L and N). Statistical analysis was performed using the F test (A
to F), Student’s t-test (G and H) one-way (D, K and N) or two-way (M) ANOVA with Bonferroni’s
post hoc test, or the F test (A to F). *P < 0.05, **P < 0.01, ***P < 0.001, n.s., not significant.
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with our cell system and that the receptors stoichiometry allowing the crosstalk between 5-HT2AR
and mGluR2 is conserved254.

V. mGluR2 and 5-HT2AR interact intracellularly
Besides attesting of the coupling of mGluR2 and 5-HT2AR assessed by the above-mentioned
BiFC assay, this experiment also showed that the distribution of the fluorescence produced by the
complementation of the two mCitrine fluorescent protein moieties held by each receptor is at the
cell borders but more importantly, intracellular (Fig. 1G). To further explore where the interaction
between these two receptors is localized, we tested RRI using two different methods:
sensorFRET, which enables quantitative measurement of FRET efficiency, and proximity ligation
assay (PLA), which permits direct detection of molecular interactions between two proteins without
the need of resonance energy transfer assays. Using the sensorFRET approach, we observed a
significant decrease of FRET efficiency between eCFP and eYFP in DOX(+) cells stably
expressing mGluR2TM4-eYFP as compared to that observed in cells stably expressing mGluR2eYFP (Figs. 5, A to C and Fig. A1). This confirms the impaired ability of the mGluR2/mGluR3
chimeric construct to physically interact with 5-HT2AR. More importantly, the FRET signal between
5-HT2AR-eCFP and mGluR2-eYFP was located intracellularly in vesicles positive for both eCFP
and eYFP fluorescence signal (Fig. 5A). Following DOX-dependent induction of 5-HT2AR-eCFP
expression, PLA signal between 5-HT2AR and mGluR2 was observed in the form of punctate
staining (Fig. 5D). Quantification of PLA dots was significantly reduced in cells induced to express
5-HT2AR-eCFP along with mGluR2TM4-eYFP (Figs. 5, E and F). As anticipated, no PLA signal
was observed in the absence of doxycycline in cells expressing mGluR2-eYFP only (Fig. 5F).
Additional internal controls included omission of one of the primary antibodies in the PLA assays
(Fig. 5F).
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Fig. 5. Intracellular localization of the 5-HT2AR-mGluR2 complex. (A to C) SensorFRET
analysis of Flp-In T-REx HEK293 cells stably expressing mGluR2-eYFP (A and C) or
mGluR2TM4-eYFP (B and C), harboring 5-HT2AR-eCFP at the inducible locus, and treated with
doxycycline. Representative live-cell confocal images at 405 nm and 458 nm excitation
frequencies (A and B), and (C) quantification of FRET efficiencies (n = 249 – 364 regions of
interest in three independent experiments). (D to F) Flp-In T-REx HEK293 cells stably expressing
mGluR2-eYFP (D and F) or mGluR2TM4-eYFP (E and F) and harboring c-Myc-5-HT2AR-eCFP
at the inducible locus were treated with doxycycline, permeabilized and stained with anti-rabbit
antibody selective for c-Myc and anti-mouse antibody selective for mGluR2, followed by incubation
with species-specific PLA probes. Representative confocal micrographs of eCFP- or eYFP-tagged
constructs and PLA signal (cyan dots, Z-stack projection) (D and E). Quantification of PLA dots
(F). Note that PLA signal was decreased in DOX(-) cells, and when primary antibodies were not
added (n = 57 – 94 cell regions of interest demarcated according to eYFP signal within previously
defined eCFP-positive cells in three independent experiments). Data are median with 95%
confidence interval (C) or mean  SEM (F). Statistical analysis was performed using MannWhitney U test (C) or one-way ANOVA with Bonferroni’s post hoc test (F). ***P < 0.001. Scale
bars, 5 µm, inserts edge ~ 14.3 μm.
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VI. Expression of 5-HT2AR augments localization of mGluR2 in endosomal
compartments
Our data thus far show that, under steady state conditions, colocalization of mGluR2 with markers
of endocytic vesicles increased upon coexpression with 5-HT2AR. However, the nature of these
intracellular compartments remains unknown. It is classically established that agonist binding and
activation of most 7TMRs usually results in the rapid removal of the receptor from the plasma
membrane by two complementary mechanisms, desensitization and endocytosis. To evaluate the
components of the intracellular trafficking pathway in which 5-HT2AR affects subcellular distribution
of mGluR2, we next tested the effect of DOX-induced expression of 5-HT2AR on colocalization of
mGluR2 with endosomal markers. Using fixed cell confocal immunofluorescence microscopy, we
found that colocalization of mGluR2-eYFP with Rab5, which regulates clathrin-mediated
endocytosis from the plasma membrane to early/sorting endosome pools, showed a modest, yet
statistically significant, increase in DOX(+) cells as compared to DOX(-) cells (Figs. 6, A to D).
Additionally, DOX-induced expression of 5-HT2AR substantially augmented localization of
mGluR2-eYFP with Rab7 as a late endosome maker (Figs. 6, E to H).
This localization of mGluR2 in Rab7 endosomes was surprising. Are those receptors directed to
degradation, or Rab7 endosomes serve as storage compartments that are deeper or later used
after endocytosis? To address that question, colocalization of mGluR2 in Rab7 endosomes was
assessed following activation of the 5-HT2A receptor. Application of DOI resulted in the reversal of
the previous pattern; mGluR2 population was now greater in Rab5 than it was in Rab7 endosomes
(Fig. 6I). This observation suggests that following activation of 5-HT2AR, a Rab transition
demobilized the Rab5 pool of mGluR2 to Rab7. It is possible that 5-HT2AR activation leads to the
migration of mGluR2 from Rab7 to Rab5 endosomes. This could explain why at basal state, i.e.
in absence of 5-HT2AR and mGluR2 ligand, the conservation of mGluR2 is maintained in late
endosomes.
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Fig. 6. Agonist activation of either 5-HT2AR or mGluR2 differentially affects mGluR2
trafficking and downregulation. (A to L) Flp-In T-REx HEK293 cells stably expressing mGluR2eYFP and harboring c-Myc-5-HT2AR-eCFP at the inducible locus were untreated [DOX(-)] or
treated with doxycycline [DOX(+)], and exposed for 60 min to DOI (1 µM). Cells were then
permeabilized and stained with anti-Rab5 or anti-Rab7 and secondary antibody, and imaged by
confocal microscopy to detect eCFP, eYFP, anti-Rab5, or anti-Rab7. Representative confocal
micrographs (A and E) and corresponding line scans (C and D, G and H), and Manders’
colocalization coefficient analysis of anti-Rab5 (A and B; n = 33 – 134 cell regions of interest in
three independent experiments) or anti-Rab7 (E and F; n = 48 – 49 cell regions of interest in three
independent experiments) and eYFP-tagged construct. (I) Manders’ colocalization coefficient
analysis between Rab5 and Rab7 in [DOX(+)] cells and treated with DOI (1 μM) (36 cell regions
of interest in two independent experiments). (J to L) FACS analysis of internalized mGlu2
receptors along with the transferrin marker. (J and L) HEK293 cells were transfected to express
5-HT2AR-mCherry alone, mGluR2-eYFP alone, or 5-HT2AR-mCherry and mGluR2-eYFP together,
permeabilized, stained with PE-Cy5-tagged anti-transferrin receptor antibody, and imaged with an
Amnis ImageStream flow cytometer. (J) Representative images. (K) Colocalization of 5-HT2ARmCherry and transferrin receptor with or without coexpression of mGluR2-eYFP (n = 4
independent experiments). (L) Colocalization of mGluR2-eYFP and transferrin receptor with or
without coexpression of 5-HT2AR-mCherry (n = 4 independent experiments). Data are mean 
SEM (B, F, I, K and L). Statistical analysis was performed using the Student’s t-test (B, F, I, K and
L). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, n.s., not significant. Scale bars, 5 µm.
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To pursue quantitative comparison of variant receptor trafficking, and to validate our previous
findings with an independent marker of clathrin-mediated endosomes, we assessed colocalization
of 5-HT2AR-mCherry or mGluR2-eYFP with the transferrin receptor, which transits through clathrincoated pits and behaves as a marker of early endosomes, using imaging flow cytometry. As above
with Rab5 and Rab7, our data show that localization between 5-HT2AR-mCherry and the
transferrin receptor was higher as compared to that observed between mGluR2-eYFP and
transferrin receptor (Fig. 6J). Additionally, we show that whereas colocalization between 5-HT2ARmCherry and transferrin receptor was not affected upon cotransfection of the mGluR2-eYFP
construct (Fig. 6K), transfection of the 5-HT2AR-mCherry construct led to a significant increase in
colocalization between mGluR2-eYFP and the transferrin receptor (Fig. 6L).

VII.

DOI and LY379268 differentially affect localization of mGluR2 in Rab5-

positive endosomes
To gain further insight into how cells control the subcellular localization of a 7TMR complexes, we
next investigated the effects of different serotonergic and glutamatergic agonists on trafficking
processes in cells coexpressing 5-HT2AR and mGluR2.
We first explored the effect of the endogenous neurotransmitter serotonin (5-HT) or the 5-HT2AR
agonist DOI on localization of mGluR2 within Rab5-positive endosomes. Our data showed that
colocalization of mGluR2-eYFP and Rab5 was significantly increased after either 5-HT or DOI
treatment in cells stably expressing mGluR2-eYFP and induced to express 5-HT2AR-eCFP (Figs.
6A, and 7A, and B). To rule out any effect of DOI on mGluR2 trafficking, we confirmed that
treatment with DOI does not affect localization of mGluR2-eYFP and Rab5 in cells stably
expressing mGluR2-eYFP and uninduced (DOX[-]) to express 5-HT2AR-eCFP (Fig. 7C).
To test whether 5-HT2AR and mGluR2 receptor heteromer is required for this trafficking event, we
used synthetic peptides with the amino acid sequence of TM4 of mGluR2 fused to the HIV
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transactivator of transcription (TAT) peptide, which determines the orientation of the peptide when
inserted in the plasma membrane. To begin with, we wanted to test whether the interfering peptide
can reduce or even prevent the interaction between 5-HT2A and mGluR2. As expected and based
on our above findings, incubation with TAT-TM4, but not with TAT-TM1 or TAT-tagged scrambled
peptide (TAT-SCR), significantly decreased FRET signal in cells coexpressing 5-HT2AR-eCFP and
mGluR2-eYFP (Fig. 7D). Notably, incubation with TAT-TM4 reduced the effect of DOI on
colocalization of mGluR2-eYFP and Rab5 (Fig. 7E). Exposure to TAT-TM4, however, did not affect
colocalization between mGluR2-eYFP and Rab5 in vehicle-treated cells (Fig. 7E). To gain further
insight into the endocytic process at work, endocytosis was pharmacologically blocked by an
inhibitor. Dynamin is a GTPase protein that is essential for membrane fission during clathrinmediated endocytosis. Dynasore acts as a potent inhibitor of endocytic pathways known to depend
on dynamin by rapidly blocking coated vesicle formation within seconds of its application. Cells
coexpressing 5-HT2AR and mGluR2 was submit to dynasore mediated endocytosis inhibition and
treated with DOI. As a result, a diminution of the effect of DOI on augmentation of colocalization
between mGluR2-eYFP and Rab5 was observed (Fig. 7F).
To validate some of above findings with a different approach, and to track mGluR2 internalization
upon different treatments, we processed the cells to flow cytometry, where cell surface localization
of mGluR2-eYFP is detected thanks to an Alexa Fluor 647 (AF647)-tagged antibody targeting an
epitope of the N-terminal of mGluR2. Surprisingly, mGluR2 surface distribution was unaffected by
DOI in DOX(+) cells (Fig. 7G). As expected, however, cell surface AF647 signal was augmented
upon dynasore treatment (Fig. 7G). This lack of effect of DOI exposure on cell surface mGluR2eYFP was further supported by radioligand binding assays. [3H]LY341495 binding was
comparable in DOX(+) cells treated with DOI and vehicle (Fig. 7H). Together with the absence of
effect of DOI treatment on FRET (Fig. 7I) and PLA (Fig. 7J) signal between 5-HT2AR-eCFP and
mGluR2-eYFP, these data suggest that whereas exposure to DOI augments subcellular
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Fig. 7. DOI and LY379268 differentially affect localization of mGluR2 in Rab5-positive
endosomes. (A to C, K and N) Flp-In T-REx HEK293 cells stably expressing mGluR2-eYFP and
harboring c-Myc-5-HT2AR-eCFP at the inducible locus were untreated [DOX(-)] or treated with
doxycycline [DOX(+)], and exposed for 60 min to serotonin (5-HT, 1 µM), DOI (1 µM) or LY379268
(10 µM), or vehicle. Cells were then permeabilized and stained with anti-Rab5 and secondary
antibody, and imaged by confocal microscopy to detect eCFP, eYFP, anti-Rab5 (Fig. 6A 3rd line).
Representative line scan of DOI treated cells (B). Cells were incubated (60 min; 10 µM) with TATfused peptide corresponding to TM1 (TAT-TM1) or TM4 (TAT-TM4) of mGluR2, or scrambled
control peptide and then processed for sensorFRET (n = 248 – 393 regions of interest in three
independent experiments) (D). (E and Q) Manders’ coefficient colocalization analysis of anti-Rab5
and eYFP-tagged construct. Cells were exposed for 60 min to DOI (1 µM, E), LY379268 (10 µM,
Q), or vehicle. TAT-tagged peptides (10 µM) were added 5 min before drug or vehicle
administration (n = 27 – 103 cell regions of interest in three independent experiments). (F, M and
O) Manders’ coefficient colocalization analysis of anti-Rab5 and eYFP-tagged construct. Cells
were exposed for 60 min to DOI (1 µM, F), LY379268 (10 µM, M and O), or vehicle. Dynasore (80
µM) was added 5 min before drug or vehicle administration (n = 28 – 88 cell regions of interest in
three independent experiments). (G, L and P) Cell surface localization of mGluR2-eYFP assessed
by flow cytometry assays with an Alexa Fluor 647 (AF647)-tagged antibody. Cells were exposed
for 60 min to DOI (1 µM, G), LY379268 (10 µM, L and P), or vehicle. Dynasore (80 µM) was added
5 min before drug or vehicle administration (n = 3 – 6 independent experiments with 8508 – 10048
cells per experimental condition). (H, R and S) Density of mGluR2 shown as [3H]LY341495 binding
in membrane preparations of DOX(+) (H and S) or DOX(-) (R) cells exposed for 60 min to DOI (1
µM, H), LY379268 (10 µM, R and S), or vehicle. Data are shown as percentage of specific binding
in DOI- or LY379268-treated cells as compared to vehicle (n = 4 independent groups of membrane
preparations). (I and J) Cells were exposed for 60 min to DOI (1 µM), LY379268 (10 µM), or
vehicle. Quantification of FRET efficiencies (I, n = 281 – 536 regions of interest in three
independent experiments). Quantification of PLA dots (J, n = 82 – 148 cell regions of interest
demarcated according to eYFP signal within previously defined eCFP-positive cells in three
independent experiments). Data are mean  SEM (A, C, E to H, K to S) or median with 95%
confidence interval (D, I and J). Statistical analysis was performed using Student’s t-test (C, H, K,
N, R, S), one-way ANOVA with Bonferroni’s post hoc test (A, F, G, L, M, O, and P and Q), twoway ANOVA with Bonferroni’s post hoc test (E), or one-way non-parametric ANOVA (KruskalWallis) with Dunn’s post hoc test (D, I and J). *P < 0.05, **P < 0.01, ***P < 0.001, n.s., not
significant.
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localization of mGluR2 within Rab5-positive endosomes through a mechanism that requires
heteromerization between 5-HT2AR and mGluR2, activation of the 5-HT2AR receptor does not
affect mGluR2 cell surface density, total density or heteromerization with 5-HT2AR.
We next tested whether DOX-induced expression of 5-HT2AR-eCFP modulates the effect of the
mGluR2/3 agonist LY379268 on mGluR2’s subcellular localization and trafficking. Consistent with
the paradigmatic description of 7TMR endocytosis after ligand binding, in DOX(-) cells, incubation
with LY379268 led to both an increase of colocalization between mGluR2-eYFP and Rab5 (Fig.
7K), and reduced cell surface AF647 signal (Fig. 7L), phenotypes that were prevented by dynasore
(Figs. 7, L and M). Importantly, this effect of LY379268 on subcellular localization of mGluR2 was
not observed in DOX(+) cells (Figs. 7, N, O and P), although dynasore augmented the surface
location of mGluR2. This effect was rescued in DOX(+) cells treated with TAT-TM4 (Fig. 7Q).
Additionally, our radioligand bindings assays with the mGluR2/3 antagonist [3H]LY341495 showed
that mGluR2 density was reduced in DOX(-) cells treated with LY379268 (Fig. 7R), whereas
LY379268 treatment did not affect [3H]LY341495 binding in cells stably expressing mGluR2-eYFP
and induced to express 5-HT2AR-eCFP (Fig. 7S). By contrast, we observed that, in DOX-treated
cells, molecular proximity between 5-HT2AR-eCFP and mGluR2-eYFP, as assessed by
sensorFRET (Fig. 7I) and PLA (Fig. 7J), was reduced upon previous exposure to LY379268.
Together, these data indicate that the 5-HT2AR agonist DOI and the mGluR2/3 agonist LY379268
differentially affect mGluR2 density as well as localization of mGluR2 with markers of endocytic
compartments in cells expressing mGluR2 alone, or together with 5-HT2AR.

VIII.

Psychedelic and non-psychedelic compounds have different effects on the

5-HT2AR-mediated endocytosis of mGluR2
Our system thus far showed that 5-HT2AR agonists such as DOI and 5-HT displaced mGluR2 to
different marked compartment of the endocytic system, and that is dependent on the 5-HT2A-
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Fig. 8. Activation of 5-HT2AR by hallucinogenic or nonhallucinogenic agonists differently
mediate Rab5-dependent trafficking of mGluR2. Flp-In T-REx HEK293 cells stably expressing
mGluR2-eYFP and harboring c-Myc-5-HT2AR-eCFP at the inducible locus were treated with
doxycycline [DOX(+)], and exposed for 60 min to DOI (1 µM), LSD (1μM), lisuride (1μM) or
ergotamine (1μM). Cells were then permeabilized and stained with anti-Rab5 and secondary
antibody, and imaged by confocal microscopy to detect eCFP, eYFP, anti-Rab5. Manders’
coefficient colocalization analysis of anti-Rab5 (n = 33 cell regions of interest in one experiment)
and eYFP-tagged construct. Data are mean  SEM. Statistical analysis was performed using oneway ANOVA with Bonferroni’s post hoc test. *P < 0.05, n.s., not significant.
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mGluR2 receptor heterocomplex. Although serotonin is not hallucinogenic at physiological
concentration, unlike DOI, we wanted to gain more insights into how propsychotic molecules such
as 5-HT2AR hallucinogens (HAL) can affect mGluR2 trafficking as compared to non-hallucinogenic
agents (NHAL). Hallucinogenic 5-HT2AR agonists such as LSD and psilocybin have been
categorized as propsychotic compounds because of their ability to mimic some of the
schizophrenia positive symptoms. Conversely, molecules that are very close in structure but not
hallucinogenic, such as lisuride and ergotamine, seem to evoke different internalization and
signaling mechanism, such as bias agonism114,352 and transphosphorylation350. Given that HAL
and NHAL have different effects on the internalization of 5-HT2AR and that it can phosphorylate
mGluR2 to affect its Gαi/o signaling and probably its internalization following exposure to the
drugs, we hypothesized that similar to those findings, HAL and NHAL would have different effects
on the internalization of mGluR2 in Rab5 endosomes in cells coexpressing both receptors.
Consistently with previous findings163,350, and similar to the findings with 5-HT and DOI, cells
treated with LSD and psilocybin tended to have a greater colocalization index between mGluR2
and Rab5 (Fig. 8) (Fig. 8). Conversely, no increase was observed with NHAL treatments such as
lisuride and ergotamine, indicating that only 5-HT2AR hallucinogenic agonists have the potency to
affect mGluR2 trafficking (Fig. 8).

IX. Exposure to clozapine down-regulates mGluR2 via GPCR heteromerization with
5-HT2AR
1. Effect of 5-HT2AR antagonists on receptor’s subcellular distribution
Recent reports suggest that presence of 5-HT2AR antagonists/inverse agonists affects intracellular
localization of 5-HT2AR constructs in living mammalian cell cultures. As an example, upon addition
of ligands such as mianserin, cells show 5-HT2ARs predominantly at the plasma membrane335. To
corroborate these findings, we used our Flp-In T-REx system expressing 5-HT2AR-eCFP only (i.e.,
without stable expression of mGluR2-eYFP, mGluR3-eYFP or mGluR2TM4) in an inducible
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manner. Following addition of DOX, cells were treated overnight with the 5-HT2AR
antagonist/inverse agonist M100907 (also known as volinanserin or MDL 100,907), or vehicle.
Our data indicated that, opposite to that observed in vehicle-treated cells, 5-HT2AR-eCFPs were
essentially localized at the plasma membrane of cells treated with M100907 (Fig. 9A to C). Similar
results were obtained with the 5-HT2AR antagonist/inverse agonist altanserin (Fig. 9A and D).
Surprisingly, the clozapine’s analog olanzapine had the same effect on the localization of 5-HT2AR
(Fig. 9A). Together, these data suggest that, at steady state, the bulk of 5-HT2AR-eCFP is present
in punctate intracellular vesicles, and that treatment with the 5-HT2AR antagonists/inverse agonists
enhances the otherwise restricted cell surface localization of the 5-HT2AR.
2. Effect of clozapine on 5-HT2AR’s subcellular distribution
Clozapine, however, is an antipsychotic medication that presents peculiar properties as it normally
behaves as a 5-HT2AR antagonist/inverse agonist, thus blocking or inhibiting 5-HT2AR-dependent
principal signaling pathways such as activation of Gαq/11 proteins, yet is also able to activate certain
pathways such as Akt. Additionally, and opposite to what is usually observed with most
antagonists and inverse agonists (see above), our data showed that following DOX-induced
expression of 5-HT2AR-eCFP, clozapine exposure did not discernibly affect the subcellular
distribution of the 5-HT2AR construct (Fig. 9A and E). Nevertheless, our previous findings in whole
animal models showed that long-lasting exposure to clozapine induces mGluR2 down-regulation
in brain regions such as the frontal cortex. Consequently, we tested whether clozapine
affectsmGluR2 localization and density in cells coexpressing 5-HT2AR and mGluR2, as well as the
extent to which 5-HT2AR-mGluR2 heteromerization is necessary for this trafficking event.
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Fig. 9. Clozapine treatment affects mGluR2 trafficking and downregulation via 5-HT2ARmGluR2. (A) Representative confocal micrographs and representative line scans of Flp-In T-REx
HEK293 cells harboring 5-HT2AR-eCFP at the inducible locus were treated with doxycycline, and
then exposed overnight to M100907 (C) (10 µM), altanserin (D) (10 µM) or clozapine (E) (10 µM),
olanzapine (10 μM) or vehicle (B). (F to H and K, J) Flp-In T-REx HEK293 cells stably expressing
mGluR2-eYFP (F, G to L, N, P, and U, V, W), mGluR2TM4-eYFP (H, L, R), or mGluR3-eYFP
(O, Q) and harboring 5-HT2AR-eCFP at the inducible locus were treated with doxycycline and then
exposed overnight to clozapine (10 µM or 50 µM) or M100907 (10 µM), or vehicle. Representative
confocal micrographs and line scans (F, G, J, K). (H) Manders’ coefficient colocalization analysis
of eYFP- and eCFP-tagged constructs (n = 30 – 74 cell regions of interest in three independent
experiments). (I) Manders’ coefficient colocalization analysis of eYFP- and eCFP-tagged
constructs in cells stably expressing mGluR2-eYFP and harboring 5-HT2AR-eCFP at the inducible
locus. Cells were treated with doxycycline, and then exposed overnight to clozapine (10 µM) or
M100907 (10 µM), or vehicle. TAT-tagged peptides were added both 5 minutes before clozapine
or vehicle administration and 65 minutes before cell fixation (n = 44 – 98 cell regions of interest in
three independent experiments). (M to O, U, V, W) Cell surface localization of mGluR2-eYFP with
an Alexa Fluor 647 (AF647)-tagged antibody (U, V, W) and mGluR2-eYFP (M, N) or mGluR3eYFP (O) density with eYFP were assessed by flow cytometry assays (n = 3 – 5 independent
experiments with 8148 – 10418 cells per experimental condition). (P to R) Density of mGluR2 (P),
mGluR3 (Q) or mGluR2TM4 (R) shown as [3H]LY341495 binding in membrane preparations of
cells exposed overnight to clozapine (10 µM), or vehicle (n = 4 independent groups of membrane
preparations). (S) Quantification of FRET efficiencies (n = 315 – 364 regions of interest in three
independent experiments). (T) Quantification of PLA dots (n = 160 – 253 cell regions of interest
demarcated according to eYFP signal within previously defined eCFP-positive cells in three
independent experiments). (W) Intracellular eYFP signal in cells stably expressing mGluR2-eYFP
and harboring 5-HT2AR-eCFP at the inducible locus. Cells were treated with doxycycline, and then
exposed overnight to clozapine (10 µM), or vehicle (n = 73 – 68 cell regions of interest demarcated
based on eCFP signal within intracellular vesicles in three independent experiments). Data are
mean  SEM (H, and I, L to R, and T to W) or median with 95% confidence interval (S). Statistical
analysis was performed using Student’s t-test (N to R, S, T, and W), one-way ANOVA with
Bonferroni’s post hoc test (M and U), two-way ANOVA with Bonferroni’s post hoc test (H, I, L), or
Mann-Whitney U test (S). **P < 0.01, ***P < 0.001, n.s., not significant. Scale bars, 5 µm.
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3. Effect of clozapine on mGluR2’s subcellular distribution
Cells induced to express 5-HT2AR-eCFP and stably expressing mGluR2-eYFP were incubated
with clozapine or vehicle. As before (see Fig. 3A, above), induction of 5-HT2AR-eCFP corroborated
a high level of colocalization between 5-HT2AR-eCFP and mGluR2-eYFP in intracellular vesicles
of vehicle-treated cells (Fig. 9F, G and L). Importantly, addition of clozapine resulted in an
observable reduction of colocalization between mGluR2-eYFP and 5-HT2AR-eCFP (Figs. 9, F and
Hand L). This effect was not observed after addition of M100907 (Figs. 9, F and I), and was
prevented by TAT-TM4 (Fig. 9I). Interestingly, and opposite to the effect observed in cells
expressing 5-HT2AR-eCFP alone (see Fig. 9A, above), both 5-HT2AR-eCFP and mGluR2-eYFP
remained intracellularly colocalized upon exposure to M100907 (Fig. 9F and J). As expected (see
Fig. 3C, above), colocalization was less observable in cells coexpressing 5-HT2AR-eCFP and
mGluR2TM4-eYFP (Figs. 9H, K, L), yet this low degree of colocalization was unaffected upon
clozapine exposure (Figs. 9F, H and L)). Together, these data suggest that clozapine, and not
M100907, reduces subcellular colocalization of 5-HT2AR-eCFP and mGluR2-eYFP through a
mechanism that requires their molecular proximity.
4. Effect of clozapine on mGluR2 density and expression and its heteromeric
association with 5-HT2AR
We next tested whether clozapine treatment affects mGluR2’s density via the 5-HT2AR-mGluR2
heteromer. Our flow cytometry analysis shows that, in DOX(+) cells stably expressing mGluR2eYFP, clozapine treatment reduced intensity of eYFP (Fig. 9F), an effect that was not observed
upon M100907 treatment (Fig. 9N) or in cells stably expressing mGluR3-eYFP (Fig. 9O). Similarly,
density of mGluR2-eYFP, as determined by binding saturation curves with [3H]LY341495, was
reduced upon clozapine treatment in cells induced to express 5-HT2AR-eCFP and stably
expressing mGluR2-eYFP (Fig. 9P and Fig. A2 A). This clozapine-dependent effect, however, was
not observed in cells induced to express 5-HT2AR-eCFP and stably expressing either mGluR384

eYFP (Fig. 9Q and Fig. A2 B) or mGluR2TM4-eYFP (Fig. 9R and Fig. A2 C). Treatment with
clozapine also diminished both FRET efficiency (Fig. 9S) and PLA signal (Fig. 9T) between 5HT2AR-eCFP and mGluR2-eYFP. Most importantly, although clozapine (Fig. 9U), but not M100907
(Fig. 9V), decreased cell surface immunoreactivity of mGluR2-eYFP, this effect was more evident
on the subpopulation of mGluR2 located intracellularly (Fig. 9W). Additional controls included
absence of effect of clozapine on cell surface mGluR2-eYFP immunoreactivity (Fig. A2 D5Q) and
eYFP signal (Fig. A2 E) in DOX(-) cells.

X. Absence of 5-HT2AR expression affects mGluR2 localization in cortical
pyramidal neurons
1. Colocalization of mGluR2 and Rab5 in mouse cortical primary neurons
Previous neuroanatomical studies showed that 5-HT2AR and mGluR2 colocalize in frontal cortex
pyramidal neurons. Our current data so far suggest that expression of 5-HT2AR modulates mGluR2
trafficking and localization in a mammalian tissue culture model. To ensure that this phenomenon
occurs in a primary cell culture system, we examined whether localization of mGluR2 in Rab5positive endosomes is affected in cortical neuron cultures of 5-HT2AR knockout (5-HT2AR-/-) mice
and wild-type (5-HT2AR+/+) littermates. Notably, colocalization of anti-mGluR2 immunoreactivity
and Rab5 was significantly reduced in cortical primary neuron cultures of 5-HT2AR-/- mice, as
compared to 5-HT2AR+/+ animals (Figs. 10, A and B).
2. Effect of 5-HT2AR expression on mGluR2 subcellular localization in mouse frontal
cortex synapses
To assess whether the subcellular localization of mGluR2 is regulated by its interactions with 5HT2AR in native tissue, we examined the distribution of anti-mGluR2 immunoreactivity relative to
the plasmalemma in the frontal cortex of 5-HT2AR+/+ and 5-HT2AR-/- mice using immunogold
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Fig. 10. Localization of mGluR2 is dysregulated in the frontal cortex of 5-HT2AR−/− mice. (A
and B) Colocalization analysis of anti-mGluR2 and anti-Rab5 immunoreactivity in cortical primary
cultures of 5-HT2AR+/+ and 5-HT2AR−/− mice. Representative confocal micrographs (A). Manders’
coefficient colocalization analysis (B) (n = 30 to 74 cell regions of interest in two independent
experiments). Nuclei were stained in blue with Hoechst 33342. (C and D) Immunogold labeling for
anti-mGluR2 immunoreactivity in the frontal cortex of 5-HT2AR+/+ and 5-HT2AR−/− mice (n = 4 mice
per genotype and 25 to 35 synapses per mouse). Representative photomicrographs showing
excitatory synapses in mouse frontal cortex (C). Quantification of relative distribution of gold
particles within postsynaptic spines (D). Data are means ± SEM (B and D). Statistical analysis
was performed using Student’s t test (B) or two-way ANOVA with Bonferroni’s post hoc test (D).
*P < 0.05 and ***P < 0.001. Scale bars, 5 μm (A) and 100 nm (C). n.s., not significant.
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labeling. We focused our analysis solely on excitatory postsynaptic dendritic spines which in the
frontal cortex region are the principal sites of glutamatergic input onto pyramidal neurons, and our
previous data showed that 5-HT2AR and mGluR2 crosstalk in this population of cortical cells.
Within postsynaptic dendritic spines, particle clusters were observed at plasma membrane, inside
the cytoplasm, or distributed on both plasmalemma and intracellularly (Fig. A3). For each synapse,
distribution was scored based on these three categories. In neurons from 5-HT2AR+/+ mice, the
largest proportion of synapses showed both plasma membrane and intracellular labeling (Figs.
10, C and D). Additionally, there was a significantly greater proportion of gold particle clusters at
the plasma membrane alone in neurons from 5-HT2AR-/- mice relative to 5-HT2AR+/+ littermates
(Figs. 10, C and D). Together, these findings indicate that subcellular localization of mGluR2 is
affected by expression of 5-HT2AR in mouse cortical pyramidal neurons.

XI. 5-HT2AR-mGluR2 fluorescence complementation in the HEK293 maturation
pathway
1. In the endoplasmic reticulum
To address whether homo or heterodimeric receptor’s complexes can be matured in the ER, we
assessed by confocal microscopy the colocalization and the codistribution of the BiFC signal with
the ER dye ER-Tracker, using the same quantitative colocalization analyses. 5-HT2A, mGlu2 and
mGlu3 homodimers complementation signals overlapped with the red dye, suggesting posttranslational assembling in this organelle (Fig.11A, B, C, E and F). More importantly, 5-HT2AmGlu2 BiFC signal colocalized with the reticulum (Fig. 11D). 5-HT2AR homodimer exhibited a
significantly higher index of colocalization index (Manders p<0.001), accounting for ±80% of
probes co-occurrence (Fig. 11E). No significant variation of mCitrine amount was measured (±0.6)
between the mGlu2 mGlu3 and 5-HT2A-mGlu2 receptor formations (Fig. 11E). The 5-HT2AR
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Fig. 11. 5-HT2AR-mGluR2 fluorescence complementation in the maturation pathway of
HEK293. (A) Quantitative colocalization analysis of BiFC signals and the endoplasmic reticulum.
(A to D) Single channel confocal micrographs of BiFC signal in HEK293 cells transfected to
coexpress 5-HT2AR-mCi-N172 and 5-HT2AR-mCi-C67 (2AN-2AC), mGluR2-mCi-N172 and
mGluR2-mCi-C67 (G2N-G2C), mGluR3-mCi-N172 and mGluR3-mCi-C67 (G3N-G3C), or 5HT2AR-mCi-N172 and mGluR2-mCi-C67 (2AN-G2C)and treated with the ER dye ER-Tracker. (E
and F) Manders’ and Pearson’s coefficient colocalization analysis of BiFC mCitrine (yellow) and
ER-Tracker (red) signal. (G) Colocalization between BiFC of 5-HT2AR-mCi-N172 and 5-HT2ARmCi-C67, mGluR2-mCi-N172 and mGluR2-mCi-C67, mGluR3-mCi-N172 and mGluR3-mCi-C67,
or 5-HT2AR-mCi-N172 and mGluR2-mCi-C67 and the Golgi apparatus 58K. Immnunofluorescence
using a primary antibody against 58K protein and secondary AF568. Arrows point white pixels
indicating positive signals for both probes. (H) Intensities distributions line scans from the
membrane to the nucleus areas. Fluorescence intensity profiles illustrate the spatial codistribution
of the two probes, BiFC and ER-Tracker. The relative similarity probes profiles in the case of 5HT2AR are consistent with relatively high and concentrated yellow pixels, as depicted by the
image. mGluRs absence of paired profiles was reflected by absence of correlation. (I)
ImageStream IFC-based BiFC of dual positive cell populations gated according to their Bright
Details Similarity scores (BDS). Orange areas represent gated colocalized cell populations after
indicated BDS calculation. Percentages of colocalized cells are shown. Images represent flowed
cells and fluorescence profiles in each population acquired with a 60x objective. n=: 5-HT2A: 579;
mGlu2: 811; mGlu3: 281; 5-HT2A-mGlu2: 974. Data are means ± SEM for 2 experiments (A to D,
and I), one experiment (G). Statistical analysis was performed using one-way ANOVA with
Bonferroni’s post hoc test (E and F) and a Pearson logarithm transformation for the BDS score
calculation (I). ***p<0.001, n.s. not significant. Scale bar is 10 μm.
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homodimer elicited a high fractional overlap with the ER dye (Fig. 11E). Probes intensity
codistribution analysis by Pearson correlation index (PCC) confirmed a relatively high index of
codistribution between the signals, suggesting a linear correlation of their intensity in the organelle
(Fig. 11F). This was supported by the intensity profiles plotted by line scans crossing the
intracellular cell’s area from the membrane to the nucleus (Fig. 11G). There was no such
correlation in the case of the mGluRs (Fig. 11F). The PCC value of the 5-HT2A-mGlu2 receptor
heteromer with the ER dye was significantly higher than the mGluR homodimers but lower than
the 5-HT2AR homodimer, suggesting a partial overlap with the ER (Fig. 11F). Noticeably, the
expression pattern of the heterocomplex was both plasma membranous and intracellular (Fig.
11D). Together, these colocalization analyses suggest that 5-HT2A and mGluR2, come in close
proximity within the ER.
2. In the Golgi apparatus
We used an immunofluorescence approach to detect the presence of the 5-HT2A-mGlu2 receptor
heteromer in the Golgi apparatus (GA) with an anti-58k antibodies targeting the resident protein
58K, conjugated to AlexaFluor568 secondary antibody. Due to the reduced area covered by the
Golgi apparatus within cells compared to that of the ER, we qualitatively assessed the presence
of the BiFC signal attesting the formation of the 5-HT2AR-mGlu2 heterocomplex (Fig. 11H).
Homomeric 5-HT2A mGluR2 and mGlu3 receptors were found is small proportion in the Golgi
apparatus, consistent with the upward flow of the protein biosynthesis (Fig. 11H). 5-HT2A-mGlu2
heterocomplex colocalized with the GA. This suggests that the heterodimer may also be matured
in the GA in relatively same proportion as the homomeric structures.
3. Image Flow Cytometry-based BiFC colocalization of 5-HT2A-mGlu2 heterocomplex
with the ER
In order to confirm previous findings in a larger cell populations, we combined IFC with BiFC in
cells transfected with paired constructs. Double fluorescent populations were analyzed by the
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Bright Details Similarity score (BDS). Negative gates were set for each complementation
experiment by colocalizing each probe with the bright field. As previously described, a BDS score
of >1.5 indicates highly colocalized cell populations254. All calculated control gates provided BDS
scores ≥ 1.5 (Fig. 11G). This score delineate the gate over which cell population can be interpreted
as highly colocalized. BDS score of 1.5 showed that 44,6% of 5-HT2A BIFC-positive population
were highly colocalizing with the ER. Scores of 1.593 and 1.594 gated mGluR2 and mGluR3
populations accounting for 12.3% and 11%, respectively. The heterodimer scored 1.532 with
60.4% of colocalized cells. Thus, this experiment distinguished consistent amount of highly
colocalized cells populations and provided a similar trend between the BiFC constructs, although
the analysis technique was different.

93

Discussion
It has long been known that coexpression of multiple 7TMRs by individual cells can affect
processes

related

to

agonist-promoted

receptor

signaling,

endocytosis

and

down-

regulation58,64,353–357. The taste receptors provide a typical example. The finding that the class C
heterodimer formed by T1R1 and T1R3 are sensors for the glutamate and aspartate amino-acid,
commonly termed umami taste, while T1R2 and T1R3 associate to sense the sweet molecules,
indicates that heteromerization is required for the perception of different taste stimuli. A change in
the ligand binding domain (LBD) conformation relays an immediate restructuration of the dimeric
interface, allowing to switch on downstream signals, which finally results in cell responses as
diverse as taste perception can be358–360. Previous studies also suggested that for many
documented 7TMRs heterocomplexes, such as -opioid-2-adrenergic361, 2A adrenergic-1adrenergic57, and adenosine A2A-dopamine D2 receptor362, stimulation of only one of the
components was sufficient to promote co-trafficking of the complex. Thus, the concept of 7TMRs
co-trafficking in heterologous systems is not new. Pioneer observations suspected the cointernalization of two opioid receptors as a 7TMRs heterodimer, which were intensively studied for
their pharmacology and their signaling as oligomers. The authors suggested that, etorphine
treatment leads to internalization of δ-opioid receptor (δOR) when expressed alone, but not when
it is coexpressed with κ-opioid receptor (κOR). However, they demonstrated that 30% of the
surface fluorescence diminished indicating that δOR homodimer can be internalized in cells
expressing both δOR and κOR. It was then proposed that heterodimerization may participate in
mGluR2 co-internalization64.
In the present study, our data suggest that expression of 5-HT2AR affects the subcellular
distribution of mGluR2 through a molecular mechanism that involves a physical interaction of the
two protomers. We further show that in the same cells, mGluR2 responds differently to processes
related to agonist-induced trafficking through endosomal compartments when expressed with 5-
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HT2AR. In addition, in glutamatergic excitatory postsynaptic elements of HTR2A-/- mouse frontal
cortex, mGluR2 subcellular distribution is maintained close to the plasmalemma, similar to the
prototypical localization observed in Flp-In T-REx stable HEK293 cells not induced to express 5HT2AR. Moreover, in cortical primary culture of 5-HT2AR-deficient mice, the colocalization of
mGluR2 and Rab5 is diminished, supporting the finding that 5-HT2AR expression favors Rab5mediated internalization mGluR2.
Under basal state experimental conditions (i.e., the dialyzed FBS used in the culture media is free
of the endogenous neurotransmitter 5-HT) our data validate the intriguing observation that 5HT2AR shows an elevated level of localization in intracellular vesicles, which could appear as an
anomalous localization compared to most 7TMRs that are primarily addressed to the surface. This
singular phenotype had previously been observed in several experimental systems, including
HEK293 and CHO-K1 cells40,88,363. By assessing, in intact COS-7 cells, the interaction between 5HT2AR and 5-HT2CR’s PSD-95/Disc-large/Zonula occludens-1 (PDZ) domains and co-transfected
pre or postsynaptic PDZ resident proteins, it was reported a prominent intracellular presence of 5HT2AR when transfected alone, as a consequence of its interaction with specific sets of intracellular
PDZ proteins364. Additionally, those protein sites together with PSD-95, being resident of the
postsynaptic element, are in accordance with the main localization of 5-HT2AR in this compartment
(see below). Although not mutually exclusive, the physical interaction of 5-HT2AR and PSD-95,
besides providing structural localization, has also a functional role: PSD-95 enhances 5-HT2ARmediated activation of Gαq signaling as measured by IP accumulation in HEK 293 cells365.
However, the direct interaction of 5-HT2AR and PSD-95 accounting for this phenotype was
interpreted in two ways: PSD-95 would anchor 5-HT2AR in clusters to the cell surface, suggesting
that its constitutive activity can be modulated by this postsynapytic proteins; and second, that this
localization would favor interactions between 5-HT2AR and other downstream effectors to elicit
agonist-induced signaling yet restricting agonist-dependent internalization of 5-HT2AR365; here,
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PSD-95 inhibits agonist-induced internalization of 5-HT2AR in order to maintain the receptor near
cell surface pools. This process is also thought to participate, through the recognition by PSD-95
of specific PDZ motifs borne by 5-HT2AR, in its proper targeting to dendrites of pyramidal
neurons366. In support of such cellular organization, it was also proposed that, similar to the
agonist-independent G protein activation of 5-HT2CR, 5-HT2AR may also have constitutive activity
in heterologous systems, although to a much lesser extent than the former receptor, hence its
intracellular localization367. Later, the constitutive activity of the 5-HT2AR has been reevaluated:
using a cell-based functional assay, a stronger turnover was measured, that could be modulated
by mutating residues in the helices 6 and 3 (interaction model) of the WT receptor18,368. Together,
these reports in heterologous cellular systems addressed the nonstandard localization of 5-HT2AR
by providing functional and structural plausible explanations. Nonetheless, the 5-HT2AR
intracellular distribution is not restricted to such systems. Some of these regions contain neurons
that express both 5-HT2AR and mGluR2. While testing the subcellular distribution following the
dendritic targeting mediated by the PDZ-binding domain of 5-HT2AR, SFV-induced exogenous
expression of 5-HT2AR was found intracellularly, within dendrites of cortical primary neurons, in
accordance with its endogenous distribution in culture366.
Immunocytochemistry studies on rat cerebellar cortex and olfactory bulb demonstrated both
intracellular and membranous expression of the 5-HT2AR protein using two different antibodies,
targeting either the receptor N-terminus or the C-terminus (both tested and exhibiting an
intracellular presence in form of puncta in S2 cells)369. In the rat spinal cord and ganglia, the
immuno-targeted 5-HT2AR was observed in small and large neurons and also interpreted as
intracellular, i.e. in “dot-like” cytoplasmic distribution370. The receptor was also immuno-reactive in
the somata and dendrites of Purkinje cells and in neural bodies of deep cellular nuclei, where
again, we could observed dot-like cytosolic patterns133.
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In the rat VTA, another study showed the prominent cytoplasmic localization of 5-HT2AR-like
immunoreactivity colocalizing with the enzyme tyrosine hydroxylase, marker of dopaminergic
neurons in this region, where 92% of the immunogold particles was detected. Neurons where TH
was not detected also displayed this intracellular pattern, and was interpreted as membrane
recycling of surface receptors, with all the caution attributed to immunogold assays 127. Given the
highly probable constitutive activity of 5-HT2AR (see above), it is possible to interpret this presence
as agonist-independent activated receptor trafficking. Additionally, 5-HT2AR immunoperoxidase
stained other organelles such as the endoplasmic reticulum, Golgi apparatus, mitochondria and
microtubules. This has also been observed in a study providing similar results in the rat cerebral
cortex, using immunogold counterstaining and colocalization with the Microtubule Associated
Protein 1A (MAP-1A)371. The authors validated previous findings addressing the large intracellular
presence of 5-HT2AR in the rat CNS123, and specified the possible link between the intracellular
enrichment of 5-HT2AR in small dendrites of pyramidal neurons and the microtubule network, as a
likely interaction with MAP-1A. This interaction could potentially generate more interactions with
intracellular signaling molecules, and could also suggest an intracellular signaling role or a
dynamic association between surface and cytosolic 5-HT2AR371. A study focused on the caudateputamen nucleus and the nucleus accumbens shell, attested that 5-HT2AR and NMDAR
colocalized in neuron’s somata and dendrites. Interestingly, the intracellular presence of 5-HT2AR
was associated with cytoplasmic organelles rather than synaptic or extra-synaptic plasma
membranes. Those neurons, assumed to be spiny striatal in the CPN and the NAc, were localized
in dendrites and immuno-reacted with the endoplasmic reticulum and mitochondria. In the
dorsolateral part of the CPN, labeling was more sharply localized in restricted areas between the
plasma membrane and along mitochondria membranes, as well as in axon terminal endosomes,
MVB, and small synaptic vesilcles372. In nociceptive neurons of rat lumbar dorsal root ganglia, 5HT2AR appeared in the cytoplasm, and at the junction of sensory and satellite cells, though also
found at the plasma membrane of larger cell bodies373. While demonstrating the putative
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interaction of 5-HT2CR with 5-HT2AR in the mPFC of rats, confocal images showed that in this
critical region, 5-HT2AR immunoreactivity was mostly intracellular374. In a study aiming to
differentiate the anti-aversive action of serotonin inputs through activation of the 5-HT2AR in the
aversive system held within the midbrain periaqueductal grey matter, immunoreactivity was
observed in both soma and dendrites of GABAergic interneurons375. The cytoplasmic localization
of the 5-HT2AR can also be found in unexpected cell types. Besides being observed in cell bodies
and dendrites of pyramidal neurons in the cortex, the receptor was detected in Schwann cells
using a newly developed monoclonal antibody targeting an epitope on the receptor N-terminal376.
In rat hippocampus, 5-HT2AR was detected in mossy fibers, indicating a presynaptic function of
serotonin on glutamate axons. Additionally, the staining suggested that the receptor could be
found on both excitatory and inhibitory neurons. Similar to the above findings, its intracellular
presence was also recognized377. The approaches using immunoreactivity depends on the
antibodies used, especially their reliability in terms of specificity378. It is possible, and often
considered as a limitation, that several antibodies raised against different epitopes of the 5-HT2AR
receptor could lead to variable labelings of different cell types and subcellular localizations.
However, the use of several antibodies at the same time followed by analysis of the matching
profiles, allowed to validate and comfort the intracellular presence of the 5-HT2AR379. The
discrepancies could be attributed to the different conformations adopted by the receptor, i.e.
different activation states that could reflect different levels of subcellular distribution: an antibody
raised against the N-terminal end of the receptor would be likely inefficient to localized internalized
vesicular receptors, because the N-terminal is in its lumen126,380.
Conversely, the 5-HT2AR was reported to be mostly located at the plasma membrane, in
heterologous cell systems261,381, or both intracellularly and at the cell surface137. In mouse cortical
neurons, both the dendritic plasma membrane and the axon cytoplasm were positive for the
serotonin receptor252. It is possible that the antibodies, used or the system itself, may contribute
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to such variations in the distribution pattern of 5-HT2AR. Another possibility is that, when the rat 5HT2AR is transfected in human cells, the trafficking proteins could not recognize its PDZ motif,
which is different among species382. In vivo, ultrastructural studies of the rat spinal cord
demonstrated a major localization of the 5-HT2AR at the plasma membrane in many subregions383.
However, the same study found substantial staining in intracellular organelles, such as
endosomes and MVB. Moreover, 5-HT2AR may take distinct functions whether localize in the
spinal cord, as opposed to the cerebral cortex or the midbrain. This could explain such differences
in its expression. In a more recent review, it was proposed and admitted that the 5-HT2AR can
actually function and traffic differently, in pre or post synaptic terminals, as well as in different cell
types384. The mixed plasma membrane/cytoplasm distribution pattern of 5-HT2AR was also
observed in the intestine385. In non-human primates, similar findings have been reported124.
Together, this collection of studies indicates that the 5-HT2AR may be found in multiple brain
regions where it adopts mixed distribution patterns, and more importantly, corroborates the
intracellular distribution of the receptor. In heterologous cell systems, either the plasma
membranous or the cytoplasmic pattern can be due to the absence of specific trafficking and
signaling interacting partners that are present endogenously in vivo386. The presence or absence
of ligand could also cause discrepancies. Moreover, the specific localization of a brain region
and/or or cell type, determines the receptor’s function; this is another point that could explain its
mixed distribution pattern. Lastly, the technique in use and how it is carried out could also affect
the results. Several hypotheses have been proposed to explain such atypical behavior for a class
A 7TMR, such as constitutive activity, intracellular signaling and as a sensor for serotonin
concentration. In accordance with our findings herein, another possibility may be explored in future
work. The basal activity of the 5-HT2AR was substancial in the stable cell line used, and this
seemed to relocalize mGluR2, in absence of agonist. While the activation of 5-HT2AR implicated
Rab5-mediated internalization of mGluR2, it is possible that the serotonin receptor plays a role in
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the internalization of unbound interacting receptors and promote their agonist-independent
internalization. This is consistent with the observation that in presence of mGluR2 agonist
LY379268, its colocalization with Rab5 is reversed. This mechanism is mediated by its
heteromerization with 5-HT2AR. Another possibility is that the heteromeric formation would signal
from intracellular compartments, offering a novel functionally never observed previously.
Most 7TMRs are trafficked through the endocytic pathway after internalization263,387. We showed
that, in the absence of 5-HT2AR or mGluR2 agonists, the glutamate receptor colocalization indexes
with endosome markers were higher when coexpressed with 5-HT2AR, as compared to that
obtained in HEK293 cells expressing mGluR2 alone. Our data also suggest that the presence of
5-HT2AR in cells stably expressing mGluR2 increased mGluR2 colocalization with different
markers of the endocytic pathway such as Rab5, Rab7, and the transferrin receptor. Considering
that colocalization of mGluR2 and Rab5 was also reduced in 5-HT2AR−/− mouse cortical primary
cultures, these data provide evidence that 5-HT2AR’s constitutive activity affects the localization of
mGluR2 within individual components of the endocytic pathway.
Although an important proportion of the 5-HT2AR population is located intracellularly, we and
others have validated the expected finding that addition of 5-HT2AR agonists, including 5-HT or
DOI, leads to activation of Gαq/11 protein-dependent pathways, such as stimulation of
phospholipase C (PLC) activity, which increases intracellular inositol triphosphate (IP3),
diacylglycerol (DAG) and intracellular Ca2+ levels251,254,388.
When HEK293 cells were transfected with both 5-HT2AR-mCherry and mGluR2-mCitrine
construct, we observed that mGluR2 is relocalized intracellularly like it is partially adopting the
pattern of the serotonin receptor. However, this was not the case for all cells cotransfected with
both constructs; while the 5-HT2AR-mCherry was localized inside all the observed cells, mGluR2eYFP was still maintained at the plasma membrane for some of them. It is likely that not all the
cells express the same exact ratio of 5-HT2AR/mGluR2 receptors. The relative stoichiometry, or
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the amount of transfected DNA penetrating the cells in terms of copies, has been shown to affect
the crosstalk between 5-HT2AR and mGluR2, responsible for the mobilization of GIRK1/GIRK4
currents as a reporter of Gαi and Gαq activation. It has been already reported that in HEK 293
cells, the relative stoichiometry between the two cotransfected receptors is critical to elicit a robust
crosstalk251,254. Because the functional crosstalk has been validated by several functional assays
(GIRK current and Ca2+ mobilization), in this study we selected clones that elicited a robust crosssignaling in addition to their intracellular colocalization. In transfected cells that express 5-HT2ARmCherry and mGluR2-eYFP, the exact number of inserted genes was not assessed, and it is
possible that the relative stoichiometry between the two receptors was not conserved. Together,
these observations provide an interesting conclusion, suggesting that, in cells, a characteristic
stoichiometry is necessary to elicit both the functional crosstalk and the co-trafficking of 5-HT2AR
and mGluR2. Further work would be required to determine what is the exact relative stoichiometry
in neurons co-expressing the two receptors and likely prone to cross-signal, and compare the
findings to the number of exogenous DNA copies inserted into the cell genome of crosstalk
positive clones.
These above considerations incline to speculate that a critical stoichiometry between 5-HT2AR and
mGluR2 can either be beneficial (i.e. physiologic) or detrimental (over/under-expressed) for the
neuron and its neurotransmission, and that the intracellular localization of 5-HT2AR is an important
factor of regulation. This is relevant to schizophrenia. Following the simplest hypothesis that
trafficking controls proteins’ subcellular spatial and temporal distribution, it is then possible that a
defect in this synchronicity may lead to unbalanced ratio of receptors, which, if maintained for a
substantial amount of time and because of the entanglement of receptor trafficking and signaling,
increase the likelihood to generate a global failure, in a form of a neuropsychiatric disorder.
The implication of subcellular trafficking in schizophrenia was the topic of several symposia where,
for the first time, to our knowledge, links were made between gene association and molecular
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mechanisms389. In particular, several themes were related to endosomal trafficking and clathrincoated dependent endocytosis, as well as the DTBNP1 gene390. In post mortem tissues extracted
from subjects with psychotic disorders, altered levels of several proteins interacting with clathrin,
AP-2 and dynamin-1, among others, have been found391. These proteins regulate lysosome
positioning and expression, endosomal trafficking and cell division (this review article lists several
other proteins implicated in trafficking and detected in genetic or GWAS association studies). The
DTNBP1 gene is cited among several other primary candidates associated or altered in
schizophrenia, such as COMT, NRG1, RGS4, GRM3, and DISC1143,392,393.
Emerging hypotheses shedded light on a possible genetic dysregulation of the trafficking
machinery and more specifically, the endosomal system, resulting in neurochemical and signaling
abnormalities390,391. It is supported by genome wide analyses that detected several genes
implicated in schizophrenia related to the endosomal trafficking, and in particular to the potential
defects of the Biogenesis of Lysosome-related Organelles Complex-1 (BLOC-1). The
dystrobrevin-binding protein 1 (DTNBP1) gene that encodes the dysbindin-1 protein, together with
MUTED, are essential components of the BLOC-1 protein complex, and has become a highly
scrutinized gene for its implication in schizophrenia317,394, as well as in cognition in healthy
subjects395. Dysbindin is widely expressed in neurons, in both presynaptic terminal and
postsynaptic densities throughout the brain395,396. It is expressed in regions known to contain both
5-HT2AR and mGluR2, such as the frontal and temporal cortexes, certain nuclei of the basal
ganglia, the hippocampus, the thalamus, the amygdala, as well as the midbrain, which receives
inputs from the claustrum that may control conditioning and sleep397, a region that also receives
main serotoninergic innervation from the DR398. Dysbindin mRNA is reduced in the dorsal
prefrontal cortex and in the midbrain of patients with schizophrenia399. In the hippocampus of those
patients, both mRNA and dysbindin protein are reduced. More importantly, this reduction in the
contribution of dysbindin in the proper functioning of BLOC-1 has been shown to affect the surface
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localization of D2R, one of the main class A 7TMRs involved in both schizophrenia
physiopathology and its treatment. The dopamine hypothesis indeed postulates that, within the
PFC, the D2R-D1R ratio is imbalanced in favor of D2R, resulting in a reduction of the cortical
excitability concomitant with a reduction of the inhibitory strength of GABA interneurons 400. In
human SH-SY5Y neuroblastoma cells and in cultured cortical neurons, the reduction in dysbindin
expression has been shown to augment the cell surface presence of D2R, but not D1R401. siRNAinduced downregulation of dysbindin decreased levels of SNAP25 and synapsin I, together with a
reduction of glutamate release, suggesting that dysbindin plays a role in exocytosis of glutamate
containing synaptic vesicles402. Similar findings have also been reported in the sandy mouse (a
natural occurring null mutation of DTNBP1)403. Other components of the BLOC-1, such as snapin
and pallidin, can respectively interact with SNAP25 and syntaxin 13401, two members of the
SNARE family, master regulators of membrane fusion404,405. It has also been proposed that, under
elevated synaptic activity, pallidin interacts with Rab5 to recycle synaptic vesicles more efficiently
in pools within early endosomes. Interestingly, in yeast, BLOC-1 may also regulate and participate
to the early endosome maturation by interacting with Rab5 homolog406. These interactions, if
altered, can also affect the dynamic and the spatial distribution of endosomes by disturbing the
actin/microtubule cytoskeleton structure407. In the case of dysbindin, it has also been shown that
the protein does not primarily regulate the endocytic trafficking, but rather influences later steps
that lead to degradation. The overcharge of D2R at the cell surface is a consequence of an
inefficient degradation capacity. Additionally, the authors also suggest that this role of dysbindin
is perhaps not strictly specific to D2R but also to other 7TMRs, in various cell types408. The
presynaptic reduction of dysbindin was also correlated with an augmentation of VGLUT-1 in the
hippocampus of more than 75% of the studied schizophrenia population. It has thus been
suspected that, because altered DTNBP1 in presynaptic glutamatergic terminals can cause
BLOC-1 to dysfunction, the augmentation of VGLUT-1 can result from a lesser degradative
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function of BLOC-1, thus providing a plausible cause of glutamate dysfunction in
schizophrenia399,409,410.
It is then tempting to speculate that a defect in receptor stoichiometry, for instance 5-HT2AR and
mGluR2, due to a defect in protein trafficking/signaling, and/or vice-versa, is a plausible
explanation for the dysregulation observed in patients with schizophrenia syndrome183. What could
be at the origin of such a breakdown of the trafficking system is beyond the scope of this study; it
is possible that persistent epigenetic alterations can cause such deleterious effects in the core
machinery of protein synthesis and recycling411,412.
Many neuropsychiatric disorders, including schizophrenia, could be caused by alterations of the
dopaminergic neurotransmission and related subcellular signaling413. Hyperdopaminergic
activation in the prefrontal cortex (i.e., increased D2/D1 ratio) associated with a lack of dopamine
tone in the striatum, may account for both positive and negative symptoms of the schizophrenia
syndrome414–416. The actual mechanism is complex but one model described that in dysbindindeficient primary cortical neurons of sandy mice, BLOC-1-mediated trafficking of D2R toward its
degradation following ligand binding, corresponded to a reduction of dopamine-induced
subcellular internalization of D2R. As a result, abundant D2R receptors at the cell surface seemed
to traffic much faster than D1R400. This excess of signaling has deleterious effects on the
GABAergic neurons by reducing their excitability in the PFC and in the striatum, and more
precisely, in the layer V of the PFC pyramidal neurons400. These defects could be the results of
the dopamine neurotransmission imbalance observed in schizophrenia400. First generation
antipsychotics have high affinity for the D2R, although atypical antipsychotics target the receptor
as well309,314,415,417,418.
In the case of a defect in the 5-HT2AR trafficking in the PFC, similar to the effects described above
on D2R, it is possible that a disruption of the constitutive activity of 5-HT2AR, either by a defect of
the endocytosis or the degradation processes, could lead to receptor overexpression and because
104

5-HT2AR seemed to co-internalize mGluR2, the latter would also be downregulated, resulting in
the loss of inhibition of glutamatergic transmission by the PFC neurons. This is consistent with the
fact that agonists of mGluR2 have a potential antipsychotic activity. Thus, it would be interesting
to search into the relationship between 5-HT2AR mGluR2 and DTNBP1, although a study has
implicated 5-HT2AR and dysbindin in humans419. This is supported by the fact that the involvement
of the HTR2A gene in the physiopathology of schizophrenia is not clear. Since neither apparent
gene mutations, nor alteration of the receptor binding properties have been clearly demonstrated,
it is possible to speculate that the regulation of the receptor is involved, rather than structural
impairments of the peptide420.
The potential role of heteromerization as the mechanism underlying the effect of 5-HT2AR on
subcellular localization of mGluR2 is supported by our findings demonstrating intracellular
localization of the heterocomplex by BiFC, PLA and FRET. Surprisingly, we could not detect any
FRET signal nor PLA association near the plasma membrane. As above-mentioned, most of the
5-HT2AR seems located intracellularly, and despite being able to elicit a fast calcium mobilization,
validating the fact that 5-HT2AR can signal from the plasma membrane (as it is difficult to imagine
that a monoamine like 5-HT crosses the plasma membrane and binds intracellular receptors),
there was low to no interactions in this area. There was though a very faint eCFP fluorescence at
the plasma membrane. This is puzzling and somewhat not consistent with the standard
localization of most 7TMRs. If these findings are consistent, it will be necessary to further examine
the role of receptor heteromers in the intracellular trafficking and signaling or 7TMRs.
Recent findings point towards instability of a family A 7TMR oligomeric interface47,48,81. Our current
data demonstrating that the assembly of 5-HT2AR and mGluR2 is able to modulate and affect
dramatically the distribution of one of them can hardly be explained by a transient interaction
lasting fractions of seconds as it has been demonstrated for other class A 7TMRs (kiss-and-fly
model)31,421–423. Here, the interclass 7TMR heteromeric assembly supports the concept that 5-
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HT2AR and mGluR2 are part of a stable receptor complex structure that is co-trafficked and can
cross-signal consistently along different experiments251,253,254,424. Our findings in the maturation
pathway, suggesting that 5-HT2AR and mGluR2 can come together in close enough proximity to
be detected by BiFC confocal microcopy support that, at least in these compartments, the
existence of a stable heteromer is conceivable. Further work, however, will be necessary to fully
characterize the dynamics of this structural assembly. Given the active and structurally preferential
TM domain involved in the homodimerization of mGluR2/3 and 5-HT2AR, a recent
photocrosslinking study addressed with high accuracy the potential TM domain at the interface of
the heterocomplex formed by 5-HT2AR and mGluR289. This indicates a potential site of stabilization
that would explain herein results especially in the surprising case of DOI activating 5-HT2ARdependent trafficking of mGluR2 in Rab5 endosomes. Although previously thought as stable, the
μ-opioid receptor dimer has recently been observed as a minor and negligible entity51. Whether 5HT2AR association with mGluR2 it is stable or not, and whether this is a limitation, has to be
addressed by additional experiments, such as single-molecule pull-down assay (SiMPull)
assay425–427.
An interesting observation was that whereas DOX-induced expression of 5-HT2AR augments the
density of mGluR2, but not that of mGluR3 or mGluR2ΔTM4, Gαi/o protein coupling induced upon
activation of mGluR2 was substantially reduced in DOX(+) cells as compared to DOX(−) cells.
Although this finding further supports specificity of the cross-talk between 5-HT2AR and mGluR2,
the exact mechanism remains to be investigated. Nevertheless, a potential explanation to
reconcile these results is the existence of a compensatory pathway to rescue mGluR2-dependent
function due to the higher degree of mGluR2 intracellular localization upon DOX-induced 5-HT2AR
expression.
Acting through 5-HT2AR, LY379268 and DOI differently affected the distribution of mGluR2 within
Rab5-positive endocytic vesicles, as well as the physical interaction between 5-HT2AR and

106

mGluR2. Thus, we found that whereas coexpression of 5-HT2AR prevented the effect of mGluR2
agonists on both mGluR2 endocytosis and down-regulation, agonist-induced activation of mGluR2
decreased its physical proximity with 5-HT2AR. Our data also support the conclusion that agonist
activation of 5-HT2AR increased the colocalization between mGluR2 and Rab5. This effect
required 5-HT2AR–mGluR2 heteromeric assembly because it was reduced by the interfering
peptide TAT-TM4. However, under the same experimental conditions, and opposite to the effects
of LY379268, both mGluR2 density and 5-HT2AR–mGluR2 heteromerization remained
unchanged. These data suggest that whereas DOI augments intracellular distribution of mGluR2
within Rab5-positive and clathrin-dependent endosomes coexpressing 5-HT2AR and mGluR2,
internalized mGluR2 is not degraded after entering the late endosomal/lysosomal pathway.
Sorting of mGluR2 into the recycling pathway could provide a potential explanation. Additional
work will be necessary to determine the population of intracellular vesicles downstream of Rab5positive endosomes responsible for increased endocytic uptake of mGluR2 without receptor
down-regulation.
In the absence of DOI, colocalization of mGluR2 and Rab5 was comparable between cells
exposed to either TAT-TM4 or the TAT-tagged scrambled peptide. This absence of effect of TATTM4 on colocalization of mGluR2 and Rab5 at steady-state conditions does not call into question
the capability of the TAT-tagged peptide to reduce 5-HT2AR–mGluR2 complex assembly. Instead,
together with the effect of TAT-TM4 preventing DOI-induced augmentation of mGluR2 localization
within Rab5-positive endosomes, these findings suggest that, in the absence of exogenous
agonists such as DOI, disruption of 5-HT2AR–mGluR2 heteromerization does not imply rapid
mGluR2 trafficking from Rab5-positive endosomes to alternative endocytic compartments.
Although discovered in the late 1950’s428, clozapine still remains the gold standard for
schizophrenia treatment429. It binds with relatively low affinity to dopamine D2R and other
monoaminergic neurotransmitter receptors, but similarly to other atypical antipsychotics, clozapine
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shows a particularly high affinity for 5-HT2AR430,431. Activation of mGluR2 by mGluR2/3 agonists,
including pomaglumetad or LY2140023 (an oral prodrug of LY404039), has been proposed to
treat tripartite symptoms in patients with schizophrenia226, but pomaglumetad did not show enough
clinical utility432. We previously proposed that chronic treatment with clozapine and other atypical
antipsychotics induces a selective down-regulation of mGluR2 expression through an epigenetic
mechanism involving repressive histone modifications at the promoter region of the mGluR2
(GRM2) gene in mouse and human frontal cortex433,434. These preclinical findings were validated
by clinical work showing the absence of therapeutic effects of pomaglumetad in patients with
schizophrenia previously treated with atypical antipsychotic medications435. Our current findings
here propose an alternative, although not mutually exclusive, explanation by which long-lasting
exposure to clozapine down-regulates mGluR2 density through a mechanism that requires its
heteromerization with the 5-HT2AR. We observed that subcellular colocalization between 5-HT2AR
and mGluR2 was reduced upon clozapine exposure. This effect was not induced by overnight
exposure to M100907, was not observed in cells stably expressing mGluR2ΔTM4 and induced to
express 5-HT2AR, and was prevented by a TAT-tagged peptide that disrupts 5-HT2AR–mGluR2
heteromerization. Similarly, clozapine, but not M100907, reduced total mGluR2 density and
mGluR2 localization at both cell surface and in intracellular compartments. Thus, continued
exposure to clozapine, but not M100907, affects mGluR2’s subcellular distribution and density
through a mechanism that requires 5-HT2AR–mGluR2 complex formation. Further work will be
necessary to better understand the trafficking pathway responsible for alterations in mGluR2
cellular distribution among 5-HT2AR–positive intracellular vesicles and plasma membrane.
In the perspective of studying repressive epigenetic mechanisms at the mGlu2 promoter, our lab
showed that in mouse frontal cortex lacking the HTR2A gene, the mRNA level of mGlu2 are also
decreased, whereas 5-HT2C and mGlu2 levels are not affected. Although these findings
demonstrate in animal model an effect of 5-HT2AR affecting mGlu2 at the transcription level, our

108

results in a cellular system showed that expression of 5-HT2AR have a tendency to upregulate
mGluR2 at the protein level. Although these two observations are distant to the mechanism of
action, both seem to be consistent, although there is no evidence yet to prove it.
Exposure of GF-62 cells to 5-HT2AR antagonists, including clozapine, has been shown to
internalize the receptor which decreased its cell surface density. Similarly, an increase in the
intracellular concentration of 5-HT2AR in apical dendrites of rat pyramidal cells has been reported,
following exposure to such drugs. An alternative mechanism to ligand-induced dynamin
dependent endocytosis has been proposed, involving caveolae436. In the present study, we
observed that in HEK293 cells induced to express 5-HT2AR, several inverse agonists/antagonists
relocated the receptor intracellular distribution to the plasma membrane area. Although it is not
clear whether the receptor is actually spanning the membrane or stationing underneath in
endosomes, only clozapine treatments seemingly failed to relocate the receptor. Even more
surprising was that olanzapine, a clozapine analog, did affect 5-HT2AR localization. Such puzzling
finding would require fine investigations on how antagonists or inverse agonists affect the
constitutive activity of 5-HT2AR. The constitutive activity of 5-HT2AR can affect ritanserin potency18.
It is also a property of inverse agonists to affect the basal activity of 5-HT2AR, while antagonist
compounds should remain “inactive”22. A study in vivo provided more insights into this particular
mode of action typical to 5-HT2AR437.
We were unable to characterize the function of our mGluR3 clones with the GTPγS assay. This is
the reason why HEK293 were transfected with the chimeric G protein qi9, in order to test
intracellular calcium release. The positive signal elicited by mGlu3 clones suggested that the cell
line held a functional receptor. To note, we observed a large presence of intracellular eYFPpositive vesicles, attesting of a constitutive activity of the mGlu3 receptor. In the second step, we
recently addressed the reason why mGluR3 was not able to efficiently mobilize Gαi protein
signaling. In several brain tissues, GTPγS assays were performed in presence of the NAM
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mGluR3. Robust signal was elicited accounting for the presence of mGluR2 and mGluR3
composite signals. Application of NAM reduced the signal elicited by LY379268 binding in the
GTPγS readout (data not shown, in progress). Together, this indicates that mGluR3 can efficiently
couple to G proteins, but for an unknown reason, this was not the case in our cell line. A consistent
analogy is provided by a study that was able to distinguish mGluR2 signaling from mGluR3230.
Considering our findings in this heterologous cellular system, the fact that over expression or
overactivation of the 5-HT2AR may as well induce over internalization of mGluR2 into more
internalized compartment is consistent with a defect of activity. It would reduce the surface
availability and the overall density of mGluR2, and likely damped the effect of antipsychotic
glutamate agonists such as pomaglumetad. Our findings showed that coexpression of 5-HT2AR
and mGluR2 elicited some populations of more internal glutamate receptors, whereas as in
average, unlike WT, 5-HT2AR-/- mice postsynaptic area, mGluR2 tends to be nearby the
plasmalemma.

Concluding remarks
Although some reported examples may reflect data overinterpretation or ambiguity due to the
system in use, the concept that class A 7TMRs form receptor complexes is supported by
numerous experimental approaches. As of yet, the functional importance of 7TMRs
oligomerization remains controversial. Our data obtained with stable expression of mGluR2 or
mGluR2/mGluR3 chimeric constructs and TAT-tagged peptides to disrupt 5-HT2AR–mGluR2
complex formation support the conclusion that 5-HT2AR affects the subcellular localization of
mGluR2 through 7TMR heteromerization. The validity of this concept is further advanced by our
findings showing alterations in mGluR2 cellular distribution in frontal cortex pyramidal neurons of
5-HT2AR−/− mice as compared to control littermates. In short, these findings illuminate the
importance of interclass heteromerization on 7TMRs localization and trafficking.
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Limitations
The relatively low percentage of FRET efficiency is also consistent with the relative proportion but
also the orientation of the fluorescent proteins. As we cannot establish a positive control to detect
what is the maximum efficiency of this system, we could not compare our signal to a standard
maximum FRETe. However, we showed that the mGluR2TM4-eYFP chimera FRETe was
reduced by 2 folds. This indicates that the interaction is less stable with the mutant or alternatively,
we cannot rule out that the mutant’s fluorescent protein is orientated differently. Orientation of the
fluorescent protein is critical for the FRET to occur and its efficiency. Another possibility is that, as
the KD of the mutant is higher than the WT (Table 1), the function of this receptor is affected and
could not change its conformation as the WT does.
Another important question was the origin of mGluR2 trafficked by 5-HT2AR. We showed that the
application of the dynamin inhibitor dynasore prevented endocytosis of mGluR2 when 5-HT2AR
was coexpressed. Additionally, BiFC and FACS experiments suggested that the 5-HT2A-mGlu2
receptor heteromer could be synthesized in the ER, and also detected in the Golgi apparatus.
Several hypotheses can be provided: the heterocomplex is stable from it biosynthesis in the ER
to the plasma membrane and it is trafficked as a stable entity; partially synthesized in the ER and
partially assembled later at the cell surface or in endosomes; or mGlu2 provides an ER exit routes
for 5-HT2AR, similar to the GABABR or β2AR, and the association is dynamic during the trafficking
or upon ligand-induced G protein activation. An known limitation to those findings using the BiFC
assay, is that complements of the fluorescent protein can be covalently fused and therefore, the
heteromeric association is irreversible438,439. This has limited our studies to the maturation
pathway, which suggested, even if the association is irreversible, that a close contact occurred.
Additional work would be necessary to delineate and ascertain the directionality and the timeline
of this association, for example by tracking 5-HT2AR biosynthesis and trafficking in mGluR2-/- mice.
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Although the HEK293 cells have been used extensively and reliably over the past decades as a
neuronal model subrogate, they are not neurons. If they do not express mGluR2 and 5-HT2AR,
they still translate 7TMR interacting proteins, scaffolds and chaperones necessary for endogenous
cellular operations and contain the basic machinery to robustly allow and maintain the structure
and the function of overexpressed 7TMRs, or other transfected or stable receptors and
transporters. It is interesting to have in mind the native receptor expressed by this cell line and
control the expression of close and studied receptors to avoid any interference440. There is no
serotonin in our DMEM, although serotonin is an important neurotransmitter and a hormone for
the kidney function. GRM2 and GRM3 are also absent though it seems that GRM2 has traces as
assessed by a microarray study440.
The question about the affinity of the mGlu2 chimera compared to the WT mGluR2 has not been
addressed in this study. Whether the difference in affinity comes from the impaired association
with 5-HT2AR or the mutant by itself, constitutes a point to address.
Colocalization analyses sometime yielded high variances among and within experiments. This is
perhaps due to the fact that not all cells elicit the same amount of 5-HT2AR-eCFP after being
induced, and because stoichiometry seems important, this can lead to a differential internalization
of mGluR2 consistent with the level of 5-HT2AR in Rab5 or Rab7.
The primary cortical cultured neurons were extracted from embryonic mice. Because we used the
total cortical area, the exact nature of the neurons analyzed by immunofluorescence is not known,
although we favored pyramidal shaped neurons in our collection.
The Pearson correlation coefficient is sensitive to the fluorescence intensity because the
correlation is maximal when intensities are linearly associated. The use of Manders coefficient
was more appropriate in those cases, and explains why the tandem was not systematically used
in this study.
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Table 1
[3H]LY341495 binding saturation curves in Flp-In T-REx HEK293 cells
DOX(-)

DOX(+)

KD

Bmax (pmol/mg prot)

KD

Bmax (pmol/mg prot)

mGluR2-eYFP

1.59 ± 0.21

36.94 ± 1.43

2.27 ± 0.15

51.81 ± 1.11

mGluR3-eYFP

1.16 ± 0.24

5.47 ± 0.30

0.68 ± 0.08

5.56 ± 0.16

mGluR2TM4-eYFP

89.4 ± 4.84

2.33 ± 0.38

105.4 ± 4.03

3.77 ± 0.38

[3H]LY341495 binding saturation curves in Flp-In T-REx HEK293 cells stably expressing mGluR2eYFP, mGluR3-eYFP or mGluR2TM40-eYFP and harboring 5-HT2AR-eCFP at the inducible locus.
Cells were untreated [DOX(-)] or treated with doxycycline [DOX(+)] (n = 2). The data are presented
as the mean  s.e.

[3H]ketanserin binding saturation curves in Flp-In T-REx HEK293 cells
DOX(-)

DOX(+)

KD

Bmax (fmol/mg prot)

KD

Bmax (fmol/mg prot)

mGluR2-eYFP

n/a

n/a

0.65 ± 0.07

3211 ± 115.9

mGluR3-eYFP

n/a

n/a

0.64 ± 0.09

3343 ± 153.7

mGluR2TM4-eYFP

n/a

n/a

0.74 ± 0.12

7923 ± 416.0

[3H]Ketanserin binding saturation curves in Flp-In T-REx HEK293 cells stably expressing mGluR2eYFP, mGluR3-eYFP or mGluR2TM40-eYFP and harboring 5-HT2AR-eCFP at the inducible locus.
Cells were untreated [DOX(-)] or treated with doxycycline [DOX(+)] (n = 2). The data are presented
as the mean  s.e. n/a, not applicable.
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Fig. A1. Average spectra and sensorFRET analysis for Flp-In T-REx HEK293 cells stably
expressing mGluR2-eYFP or mGluR2 TM4-eYFP, and harboring 5-HT2AR-eCFP at the inducible
locus. (A and E) Linear unmixing of the eCFP (donor) component from the raw spectra, the ratio
of which provides the alpha parameter used in the sensorFRET analysis. (B and F) Fitting of the
β parameter, which is the difference between the 405 and 458 nm spectra after scaling 405 by α.
(C and G) Raw spectra at both frequencies after the acceptor direct excitation component is
removed using β339. (D and H) Linear unmixing of the donor and acceptor from the corrected
spectra, where the FRET efficiency is proportional to the ratio of acceptor magnitude to donor
magnitude. It can be seen that the ratio of eYFP magnitude to eCFP magnitude is larger in the
mGluR2-eYFP group (indicating a higher FRET efficiency) compared to the mGluR2ΔTM4-eYFP
group.
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Fig. A2. Effect of clozapine on mGluRs density. (A to C) Flp-In T-REx HEK293 cells stably
expressing mGluR2-eYFP (A), mGluR3-eYFP (B) or mGluR2ΔTM4-eYFP (C) and harboring 5HT2AR-eCFP at the inducible locus were treated with doxycycline, exposed overnight to clozapine
(10 µM), or vehicle, and harvested to perform radioligand binding assays with the mGluR2/3
antagonist [3H]LY341495 (n = 4 independent groups of membrane preparations). Cell surface
localization of mGluR2-eYFP with an Alexa Fluor 647 (AF647)-tagged antibody (D) and total
mGluR2-eYFP signal (E) density were assessed by flow cytometry assays (n = 3 – 5 independent
experiments). Data are mean  SEM. Statistical analysis was performed using the F test. ***P <
0.001, n.s., not significant.
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Fig. A3. Representative photomicrographs showing excitatory synapses in mouse frontal cortex
scored as membrane only (A), intracellular only (B), or both (C) based on postsynaptic distribution.
Scale bars, 100 nm.

(Fig. Appendix .3)
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